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ABSTRACT 
 
Flannery, Tiffany L. M.S. Department of Biological Sciences, Wright State University, 
2017. Enhanced Neurogenesis in Subventricular Zone of Rats That Voluntarily Ingest 
Fluoxetine and Simvastatin Combination Treatment. 
 
 
 
Stroke is one of the leading causes of deaths as the risk factors, both controllable and 
uncontrollable, are many. We first concentrated on a stress-free way to deliver the drugs. 
Our preference was to have the animals ingest the drugs, which led us to a reliable 
method for orally administering medication to the animal models. Using three different 
drug combinations, we tested the effects on neurogenesis without stroke. We found the 
drug combination of Fluoxetine/Statin/Ascorbic acid increases neurogenesis 19 fold 
when compared with control. Lastly, we looked at the gene changes in the cortex of the 
animal models that had been administered our drug treatment. We noted that the 
fluoxetine treatment group was involved in up-regulated genes showing genetic themes 
related to molecular functions for channel activity and that the fluoxetine/statin 
combination treatment group was associated with clotting activity as well as an immune 
response. 
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Introduction 
 
Stroke is one of the leading causes of deaths worldwide and although functional 
loss depends on the type of stroke and location, severe strokes can be fatal [1]. In the 
United States alone, 700,000 strokes occur every year [2]. The three different kinds of 
stroke are ischemic, hemorrhagic and transient ischemic attack (TIA) [3]. The loss of 
blood flow to an area of tissue constitutes ischemic stroke, while the leaking of blood into 
tissue defines hemorrhagic stroke. Ischemic stroke is caused by a thrombus or an 
embolus. A thrombus forms in a blood vessel or the heart but does not travel to any other 
part of the body, while an embolus travels to an alternate part of the body. Both are blood 
clots that can adhere to the sides of a vessel and cut off blood supply and oxygen to 
surrounding tissues. Hemorrhagic stroke occurs when a vessel inside the brain bursts and 
leaks blood into the adjacent tissues [3]. TIAs are sometimes called ‘mini strokes’ and 
often precede a stroke. Forty percent of people who suffer a TIA will also suffer a stroke 
in the future [3]. 
Roughly 1 in 19 deaths in the United States are attributed to stroke [4]. Some of 
the more obvious risks include controllable factors such as, high blood pressure, tobacco 
use, diabetes mellitus, high cholesterol, a sedentary lifestyle and obesity. According to 
the National Stroke Association, stroke can occur at any age but is more common in older 
people, with this risk doubling every 10 years, starting at the age of 55, making [3] 
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age, an uncontrollable factor, one of the biggest risks. Other uncontrollable factors are 
gender, heredity and race, as well as a prior stroke. Having a prior stroke, even a TIA, 
exacerbates risk of future stroke [5]. For our purposes, we will focus on the treatments 
and risks of ischemic stroke. 
Treatment for ischemic stroke can range from thrombolytics and aspirin (an anti- 
platelet) administered acutely to retrieval devices. Thrombolytics, like the tPA (tissue 
plasminogen activator) alteplase, can only be helpful when administered quickly within a 
small window of time. They work by breaking down the clots so that the hypoxic tissue 
can reperfuse [3]. The limited amount of time between stroke onset and the necessary 
administration of tPA highlights the importance of recognizing the signs of stroke as 
quickly as possible. Figure 1 shows the mechanism of action of thrombolytic drugs. 
Tissue plasminogen activator does not come without risks. One in fifteen people may 
develop hemorrhaging and 1 in 30 can be harmed more than helped by the treatment [2]. 
 
 
Figure 1 Mechanism of action of thrombolytic drugs. 
Step 1: tPA binds to fibrin on the surface of the clot. Step 2: This activates fibrin-bound plasminogen. 
Step 3: Plasmin is cleaved from the plasminogen associated with the fibrin. Step 4: Fibrin molecules 
are broken apart by the plasmin and the clot dissolves. Source: Klabunde, Richard E. 
Cardiovascular Pharmacology, Thrombolytic (Fibrinolytic) Drugs 2007; 
http://www.cvpharmacology.com/thrombolytic/thrombolytic. 
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Aspirin is an NSAID (non-steroidal anti-inflammatory drug) that also acts as an 
antiplatelet. As an anti-platelet, it decreases the production of prostaglandins, which 
ultimately decreases the production of Thromboxane A2 (TXA2) further down the 
cascade. Salicylic acid, an active metabolite in aspirin, has been used for centuries to treat 
ailments such as fever, pain and inflammation [6]. In Figure 2, the mechanism of action 
for aspirin is shown by the inhibition of cyclooxyegenase-1 (COX-1). The key ingredient 
in aspirin is acetylsalicylic acid, which adds an acetyl group to COX-1, through an 
irreversible reaction and will inhibit the synthesis of prostaglandins [7]. Recent studies 
have shown that aspirin also plays a role in eNOS (endothelial Nitric Oxide Synthase) 
recovery and sustainability [8]. 
 
 
Figure 2 The mechanism of action for aspirin is shown by the inhibition of cyclooxyegenase-1. 
Aspirin inhibition of COX-1 decreases TXA2 production. Source: Gasparyan, A. Y. et al. J Am Coll 
Cardiol 2008;51:1829-1843 
 
 
If the clot is in a position to be retrieved, there are a couple of devices, which 
could be used, and each comes with its own challenges. The MERCI retriever 
(Mechanical Embolus Removal in Cerebral Ischemia) was the first to be approved by the 
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FDA [9]. The MERCI retriever has a corkscrew on the end of guide and uses suction to 
dislodge and remove the occlusion. A challenge to using the device is the need to get 
distal to the embolus for effectiveness [10]. The Penumbra clot retrieval system has a 
vacuum located at the tip of the device and does not require distal deployment. Instead, 
the device is guided to a position that is proximal to the clot and is then aspirated until 
completely removed [11]. A third retriever, Solitaire Flow Restoration Revascularization 
Device, claims to restore flow, retrieve the clot and revive the tissue [12]. In trials, the 
Solitaire device outperformed the MERCI with overall better clinical outcomes and 
safety [13]. 
Even with the success of devices, the standard in care remains intravenous tPA 
within the 4.5-hour window following stroke onset. It has proven difficult to predict a 
patient’s success with retrieval devices and decisions are made on an individual basis 
[14]. Most studies conclude that energy should be focused on shortening the time 
between onset and treatment. While the standard window for tPA treatment is around 4.5 
hours, the timeframe for device retrieval is about 8 hours from onset [10]. 
The American Heart Association has been working to reduce the incidence of 
acute ischemic stroke and the injuries caused by this event. The approach includes public 
education as well as strict guidelines and shared protocols for health professionals at 
every level. The most important detail in both public and professional education has been 
stroke sign identification and immediate action. Less than 50% of 9-1-1 calls related to 
stroke victims were made within the first hour of onset and less than half of those callers 
knew that the symptoms they were reporting were indicative of stroke [15]. 
5  
Public education about the warning signs of stroke has used a couple of 
approaches. One campaign urged remembering the “5 suddens”. There are five early 
stroke warning signs including sudden weakness, sudden speech difficulty, sudden visual 
loss, sudden dizziness and sudden severe headache [16]. More recently, the message has 
moved back to FAST. FAST refers to facial droop, Arm weakness, Speech difficulty and 
Time to call 9-1-1 [17]. Although not all of the symptoms of stroke are included in the 
FAST acronym, one study claimed that 88.9% of the ischemic strokes and TIAs were 
identified with one or more of these symptoms [18]. 
Time cannot be emphasized enough to the public and calling for emergency 
transport tags the patient as a high priority. In order for stroke to be properly diagnosed, a 
physical exam and imaging scans must be performed. The patient arriving by EMS 
(emergency medical services) will be seen by a doctor sooner and have imaging done 
faster, which in turn means the stroke will be able to be treated quicker. This is important 
due to the critical window for treatment with tPA [19]. At this time, only 53% of stroke 
patients use EMS [20]. 
Other benefits for using the EMS system include the evolving guidelines for 
improving stroke care, involving the organization of both private and public resources. 
The implementation strategies ensure that stroke patients will receive the quickest and 
most effective care available within a certain period [21]. With time being the main 
variable with respect to positive outcome, using the EMS system is of the utmost 
importance because while the patient is being transported a variety of timesaving tasks 
can be performed. Patient history, starting an IV, blood samples and glucose levels can 
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all be accomplished in route to the emergency room. Having the hospital expecting the 
patient cuts down on time between onset of stroke and actual stroke treatment [22]. 
With all of the emphasis put on the critical treatment window characteristic of 
stroke, it is necessary to find methods we can use after this window has passed. Research 
has focused effort on animal models in hopes of finding a delayed treatment for stroke 
that will increase neurogenesis and recover lost functionality. For this research, we used 
an aged rat animal model, with animals over a year old, to simulate the average age of 
stroke in humans. Although stroke can occur at any age, almost 75% happen over the age 
of 65 [23]. After trying to induce stroke by a distal electrocoagulation in the MCA and 
performing immunohistochemistry to label for neurogenesis, we found no sign of infarct 
and only the effects of Doublecortin labeling. We then used these animals as surgery 
shams, since a stroke was not induced but the rest of the procedure matched that for 
inducement of stroke. Our focus turned to stimulating and quantifying changes in 
neurogenesis through various pharmacological treatments, as well as examining any gene 
alterations that may take place in response to the treatment. 
The Experiment 
 
We wanted our animal model to be comparable to the human condition. Using 
aged rats was the first step. Rats typically have a lifespan of roughly 2 years [24], so a 
one-year-old rat is considered middle-aged, and our lab has evidence that female rats at 
this age are typically post-menopausal. We had three Hypotheses and three Specific Aims 
in this thesis: 
Hypothesis 1. Removing stress through a voluntary feeding method will enhance 
the ability of the drugs to work. 
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Specific Aim 1. Develop a drug delivery method that enables rats to orally take a 
fixed dosage (mg/kg) of medicine over a period of time. 
Hypothesis 2. Statins and/or Selective Serotonin Reuptake Inhibitors will act to 
increase neurogenesis in the Subventricular Zone of aged rats. 
Specific Aim 2. Test four treatment groups to determine if the drugs increase 
neurogenesis in the Subventricular Zone of age rats. The four treatment groups will 
include control (no drugs, just vehicle), Statin combo (0.5mg/kg simvastatin, 20mg/kg l- 
arginine and 20mg/kg ascorbic acid) treatment, Fluoxetine treatment (5 mg/kg fluoxetine) 
and Fluoxetine combo treatment (0.5mg/kg simvastatin, 20mg/kg l-arginine and 20mg/kg 
ascorbic acid, 5 mg/kg fluoxetine). 
Hypothesis 3. The FDA approved drugs (statins and SSRIs) used in this study are 
working through currently unknown mechanisms to increase neurogenesis. 
Specific Aim 3. Look for rat Gene Chip changes in response to drug treatment in 
cortical tissue. 
Typically, when the brain is injured, the natural response includes injury-induced 
neurogenesis, synaptogenesis and angiogenesis, to aid in the recovery as quickly as 
possible [25]. During neurogenesis, neuroblasts develop from a neural stem cell 
population in the subventricular zone (SVZ) of the lateral ventricles or the dentate gyrus 
(DG) of the hippocampus. The subventricular zone can be found along the outer walls of 
the lateral ventricles [26]. From here, the neuroblasts migrate to the Olfactory bulb via 
the Rostral Migratory Stream, where they typically become interneurons [27]. Figure 3 
shows the path the neuroblasts travel [27]. Injury induced angiogenesis, synaptogenesis 
and neurogenesis work together as endogenous recovery mechanisms to support healing 
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of the damaged area [28]. When the neuroblasts arise and their amount of chemokine 
exposure during migration, determines whether they become astrocytes, 
oligodendrocytes, neurons or interneurons [29]. 
 
 
Figure 3 Neuroblasts path of travel. 
a | In rodent brains, postnatal neuronal migration is evident in three main areas: the cerebellum 
(CB), the hippocampus (Hipp) and the rostral migratory stream (RMS). A small number of neurons 
also complete their migration into the hypothalamus (Hyp) at) at around the time of birth. Distinct 
germinal zones (green) give rise to neurons that migrate to adjacent target zones (red). Lighter shade 
indicates that migration in these regions occurs primarily during the very early postnatal period and 
does not persist into adulthood. Cells born in the anterior subventricular zone (SVZ, inset) initiate 
their migration from the SVZ (1) as chains (2) streaming towards the olfactory bulb (OB), where 
they end their migration (3). b | A highly restricted pattern of neuronal migration is evident in the 
postnatal human brain. There are pools of neural precursors (green) around the walls of the lateral 
ventricles (V). Occasional, TUJ1 (beta III-tubulin)-positive, elongated neurons (red dots), 
reminiscent of actively migrating ones, have been identified adjacent to these precursor pools, but 
whether these represent migrating neurons is unclear. Although there is no RMS in humans, isolated 
new neurons have been reported in the olfactory bulb. In the hippocampus, sub granular zone 
precursors continue give rise to new neurons, which then migrate short distances to the adjacent 
dentate gyrus (DG). As in rodents, human cerebellar neuronal migration is limited to the very early 
postnatal period. EGL, external granule cell layer; IGL, internal granule cell layer; OE, olfactory 
epithelium; SGZ, sub granular zone [27] 
During ischemic stroke neuroblasts abandon the normal migratory path from the 
SVZ and are guided by a cascade of molecular signals toward the ischemic tissue [30]. 
This process begins 3-4 days after stroke and can continue for as long as 4 months [31]. 
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Time-lapsed imaging and labeling with Dil (di-alkyl indocarbocyanine dye) has shown 
these new neurons have retained the ability to divide [30]. In order to influence recovery 
after stroke, it becomes important to find treatments that stimulate this stem cell 
population. 
Simvastatin 
 
HMG-CoA reductase inhibitor (3-hydroxy-3-methylglutaryl) is a cholesterol- 
lowering agent from a family of drugs called statins [32]. Patients being treated with 
statins are shown to have a resistance to myocardial as well as cerebral infarctions 
(stroke) because this prophylactic treatment augments cerebral blood flow, reduces 
infarct size and improves neurological function through selective up-regulation of 
endothelial NO synthase (eNOS) [32]. Scientists found that these lipid-lowering drugs 
actually have many effects outside of improving cholesterol levels including enhanced 
neurogenesis, synaptogenesis and angiogenesis [33]. These effects have been shown 
experimentally in rats when treated after 24h (delayed) in a middle cerebral artery 
occlusion (MCAO) in Dr. Michael Chopp’s laboratory [33]. In this study, 
immunohistochemistry labeling included BrdU (label for neurogenesis), von Willebrand 
factor (endothelial cell marker) and synaptophysin staining (marker for synaptogenesis) 
and to determine neural phenotype; double immunochemistry staining was performed to 
discern BrdU with the specific progenitor marker, TUJ1 (a marker for an immature 
neuron) [33]. Testing for vascular endothelial growth factor was done using a VEGF 
ELISA kit and as a complementary measurement of angiogenesis, a corneal angiogenesis 
assay was done. The results from all tests indicated that statins induced increases in 
angiogenesis, synaptogenesis and neurogenesis [33]. 
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A study performed in 2011 with simvastatin (1mg/kg), induced angiogenesis in 
the hippocampus of rats, which were given a brain injury or sham surgery. Again, it was 
a delayed treatment with the statin starting one day after operation and continued for 2 
weeks [34]. Simvastatin was found to mediate angiogenesis through the VEGFR- 
2/PI3k/Akt/eNOS pathway. Simvastatin stimulates phosphorylation of eNOS and 
activates this pathway [34]. For eNOS activation to be enhanced, eNOS must be 
phosphorylated and statins stimulate the coupling of eNOS and Hsp90 (heat shock 
protein), which phosphorylates the eNOS [35]. Statins may reduce the effect of stroke by 
up-regulating eNOS [32]. 
The graph in Figure 4 shows where simvastatin was used to treat mice with 
normal cholesterol levels for 14 days at 0.2, 2.0 and 20 mg/kg before MCAO. The results 
illustrate that infarct volume decreased as the dose of statin increased. 
 
Figure 4 The effects of Simvastatin on cerebral infarct. 
The effects of Sim (0.2, 2.0 or 20 mg/kg s.c. daily for 14 days) on cerebral infarct volume after 2 h of 
filamentous MCA occlusion and 22 h of reperfusion compared with vehicle-injected 129/SV mice. 
Cerebral infarct volume was determined quantitatively by TTC staining. Smaller infarct sizes were 
confirmed with an indirect method that corrects for brain swelling (n=9-18 per group). 
*p<0.05;**p<0.01 (Endres et al., 1998) 
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More promise was shown with statins when studies were performed with 
atorvastatin. Administration of atorvastatin to rodents 1 day after stroke, led to significant 
increases in vascular endothelial growth factor (VEGF), cell proliferation and 
neurogenesis [33]. VEGF is an angiogenic factor and plays a role in vascular 
permeability [36]. Several growth factors, including VEGF, are expressed after cerebral 
ischemia. These growth factors induce endothelial cells to proliferate, triggering 
angiogenesis [37]. VEGF induces the expression of endothelial nitric oxide synthase 
(eNOS) [38]. To stimulate angiogenesis, eNOS produces low concentrations of nitric 
oxide NO [37], which acts to dilate blood vessels, increasing blood flow. 
The pleiotropic effects of statins, shown in Figure 5, have been found to reduce 
inflammation, platelet aggregation [25] and regulate glutamate metabolism to decrease 
excitotoxic effects, as well as contribute to the immune system via reductions in 
expression of major histocompatibility complex II (MHCII) [39]. Atorvastatin, lovastatin 
and simvastatin were also shown to directly affect apoptosis by decreasing the 
prenylation of p21 in Rho B, a small GTPase that plays an important role in regulating 
this pathway [40]. HMG-CoA reductase inhibitors induce apoptosis by reducing the 
isoprenoid concentration, which then reduces protein prenylation [40]. Other studies have 
found them reducing insulin-like growth factor (IGF-1) and platelet derived growth factor 
(PDGF) in order to decrease apoptosis [41] [42]. 
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Figure 5 Pleiotropic effects of statins on the vasculature Clinical Science (2003) 105, 251-266 
 
Statins have been shown to improve endothelial function even without a change in 
cholesterol levels, suggesting an alternate mechanism in play. At this time, stroke is 
treated prophylactically with agents that block the clotting cascade, but this type of 
treatment is risky as a person ages, as falls could lead to prolonged bleeding. This 
treatment is limited in that it decreases incidence, but not the size of the infarct [32]. 
Furthermore, experiments with alternate means of lowering cholesterol (e.g. reduction at 
the liver) have not had an impact on infarct size in stroke or positive outcome following 
myocardial infarction [32]. 
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Fluoxetine 
 
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). It works through the 
CNS, acting to increase the neurotransmitter serotonin in the synaptic region. After 
neurotransmitters are released into the synaptic cleft, they will attach to a serotonin 
transporter on the original neuron that released it. The molecules attaching to adjacent 
neurons either excite or inhibit them, while the molecules attaching to their home neuron 
are taken back up into the neuron and repackaged for release. This reuptake process 
removes excess neurotransmitter from the synapse as well as providing a means of 
efficiently recycling neurotransmitter for the cell. 
Fluoxetine was first approved by the FDA in December 1987 for the treatment of 
depression and has since been used to treat a multitude of disorders including bulimia, 
anxiety and obsessive-compulsive disorder (OCD) to name a few [43]. Patients suffering 
from stroke and Alzheimer’s are also treated with this drug [44]. 
Acute stroke causes irreversible damage to an ischemic core. The area around the 
core is called the ‘Penumbra” and is the target for treatment because it is the salvageable 
tissue [45]. When the brain is injured, an inflammation response will occur stemming 
from the release of pro-inflammatory cytokines from activated microglia. Microglia are 
part of a healthy immune defense response in the CNS. During their resting state, they 
carry out maintenance, homeostatic and surveillance roles [46]. However, when the brain 
becomes injured their structure and function will change, becoming activated and they 
will become phagocytic, and secrete cytokines and pro-inflammatory factors [47]. 
Fluoxetine has been shown to protect mesencephalic, dopaminergic and hippocampal 
neurons by mediating the inflammatory properties of microglia in culture. Fluoxetine 
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suppresses the microglia inflammatory response, which inhibits the production of pro- 
inflammatory factors such as TNFα, IL-1β, NO, and ROS (reactive oxygen species) [47]. 
Depression is one of the most common disorders that follow stroke and will pose 
limitations on recovery and rehabilitation [48]. Depression may be associated with 
reduced neuronal plasticity [49]. In 2000, antidepressants were shown to have effects on 
plasticity by increasing neurogenesis in the rat hippocampus [50] . The hippocampus is 
the one of two sites for neurogenesis, through the lifetime, in both animals and humans 
[51]. Aging has a significant effect on neurogenesis, diminishing it as we get older, and 
these results were shown in rodents 8 months old [49]. Fluoxetine can induce changes in 
the expression of PSA-NCAM, (polysialylated form of the neuronal cell adhesion 
molecule) in middle-aged rats. When PSA-NCAM expression is increased, it is 
accompanied by an increase in synaptophysin. Synaptophysin modulates plasticity and 
PSA-NCAM has been shown to promote neural plasticity in rats because of its anti- 
adhesive properties. PSA-NCAM modulates spacing between cells, regulating the 
connectivity of interneurons and influencing synaptogenesis [49]. 
Depressed patients show a decrease in synaptophysin, which means that plasticity, 
is affected. Stress shows the same effects on plasticity and neurogenesis as depression 
[52] and BDNF expression is reduced in response to stress [53]. Chronic treatment with 
antidepressants completely blocked the stress induced down regulation of BDNF [54], 
which could cause a loss of neurons in this region. Continued depression or stress without 
treatment reduces the size of the hippocampus, causing atrophy through a loss of neurons 
[55]. Figure 6 shows results from a study analyzing the effects of fluoxetine on different 
parts of the brain. 
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Figure 6 Effect of fluoxetine treatment on different structures in the brain. 
Graphs showing (A) the body weight change through the experiment for the control and fluoxetine 
group and (B) the effect of the chronic fluoxetine treatment on the volume of the different structure 
studied. Statistically significant (*P < 0.05, **P<0.01 ***P<0.001) Student t-test. Guirado et al. BMC 
Neuroscience 2012 13:5 doi: 10.1186/1471-2202-13-5 
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Since we were using simvastatin and fluoxetine for our drug treatments, we 
decided to add ascorbic acid, as well. Ascorbic acid (vitamin C, an antioxidant) was 
added because we thought it might enhance the overall effects of the drug combination. 
Ascorbic acid improves the effects of fluoxetine by decreasing the oxidation of serotonin 
[56]. This prolongs the life of the serotonin. Statins stimulate eNOS that will then 
increase BDNF [57] [32]. However, eNOS can be sensitive to oxidation and ascorbic acid 
has been shown to enhance activation of this enzyme [58] [59]. Figure 7 shows how 
ascorbic acid can boost the production of NO by eNOS when added to the calcium 
ionophore A23187 compared to the ionophore alone. 
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Figure 7 The effect vitamin C treatment has on eNOS. 
Treatment with vitamin C (100µM) increases agonist-stimulated synthesis of nitric oxide (NO) by 
eNOS. The calcium ionophore A23187 (2µM) was used to stimulate maximal production of NO by 
eNOS. The eNOS inhibitor L-NAME (300µM) inhibits the reaction, which illustrates a direct effect of 
vitamin C on eNOS activity. Controls with vitamin C alone, L-NAME alone, or A23187 + L-NAME 
were not statistically different from the control treatment (data not shown). NO was measured by 
conversion of L-[24C]-arginine to L-[24C]-citrulline (n=3). *P <0.01; **P=0.05 compared with control 
[60] 
 
 
Doublecortin, DCX 
 
Doublecortin (DCX) is a microtubule-associated protein (MAP) that is encoded 
by the DCX gene. It is transiently expressed in both the CNS and PNS during embryonic 
and post-natal development [61]. DCX is expressed in the immature neurons and their 
precursor cells while dividing and the daughter cells continue the expression for 2-3 
weeks [61]. It is considered a MAP because it colocalizes/coassembles with microtubules 
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and has the ability to directly affect the polymerization of tubulin, instigating the 
formation of microtubules [61]. 
At the ends of neuritic leading processes, there is a high concentration of DCX, 
suggesting an association with plasticity, migration, axonal guidance and dendritic 
sprouting [62]. Normal migration will not occur with disruption of the DCX gene [61]. 
During neuronal migration, the microtubules, within the growth cone mediate the 
growth cone response to chemoattractants and chemorepellents [63]. Interestingly, DCX 
does not bind microtubules throughout the neuron, but rather only those in the growth 
cones [64]. This is surprising as there is no local microtubule-organizing center (MTOC) 
in the growth cones. Experiments where tubulin was incubated with DCX showed 
microtubule nucleation, however the growth rate was not affected. The C-terminal 
domain of DCX stimulates the addition of tubulin dimers thereby catalyzing the growth 
of microtubule. The N-terminal domain of DCX binds the polymers and helps prevent the 
microtubule from disassembling [64]. When the concentration of DCX is increased, 
microtubules become more stable and do not disassemble [65]. DCX binds between the 
protofilaments and the stabilization comes from the increased integrity of the lateral 
contacts [66]. This stabilization provides a two-fold benefit. First, it allows the 
microtubules to maintain their role as tracks for motor proteins while simultaneously 
providing integrity to the outreaching growth processes [65]. 
After migration, there is a vast decrease in DCX expression, probably regulated 
by an extracellular signal [61]. This timeframe of expression between migration and final 
destination has allowed the DCX protein to become the gold standard in 
immunochemical labeling for neurogenesis [67]. 
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Endothelial Nitric Oxide Synthase, eNOS 
 
Endothelial nitric oxide synthase (eNOS) serves as a protectant in vascular 
smooth muscle [68]. ENOS is anti-thrombotic, anti-inflammatory and anti-proliferative 
for smooth muscle in the blood vessels. A lack of eNOS leads to platelet aggregation, 
increased smooth muscle proliferation, greater leukocyte adhesion to the endothelium and 
a rise in blood pressure [68]. Up-regulation of eNOS will lead to an increase in 
circulating endothelial progenitor cells (EPC) [68]. From here we will focus on ischemic 
stroke and the role that eNOS plays in the condition. 
While no genetic determinations have been pinpointed, eNOS has been linked in a 
positive way to recovery from ischemic stroke. Links between stroke and recovery are 
bridged by physical activity, statins, hypothermia, nitrite reduction and their influence on 
eNOS. 
During physical training, we strengthen our cardiovascular systems. Those who 
exercise regularly are less likely to experience an adverse cardiovascular event [69]. In 
addition, cardiovascular exercise leads to an increase in eNOS and in turn, endothelial 
progenitor cells (EPC), both circulating and in bone marrow (Fig. 8). Together eNOS and 
EPCs promote vascular health by boosting angiogenesis, reducing atherosclerosis and 
supporting vascular repair [69]. 
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Role of NO in Exercise-Induced EPC Regulation 
 
 
 
Figure 8 The role of nitric oxide in exercise-induced EPC regulation. 
(A) mRNA expression in aortic segments on day 0, 1,7,14 and 28 of training. Mean ±SEM, n=8; 
*P<0.05. Effect of 28 days of exercise on EPCs in peripheral blood (B), bone marrow (C) and 
spleen [70] 
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The enzyme eNOS is critical under ischemic conditions. It is necessary for 
arteriogenesis and angiogenesis to compensate for the loss of blood in tissues. Mice 
lacking eNOS will not recover from stroke sufficiently and will continue to exhibit 
deficits. In addition, statins will not assist in the angiogenesis of mice lacking in eNOS 
[71]. Local delivery of an adenovirus containing an active form of eNOS assists in 
improving both functional and structural deficits incurred from stroke [71]. 
When ischemia occurs, the endothelium of blood vessels becomes injured. Once 
reperfusion begins, a cascade of events, including the release of cytokines and free 
radicals, further contribute to the damage [72]. Reperfusion injury is a common 
occurrence. During reperfusion, there is inflammation and endothelial dysfunction, 
allowing for increased blood brain barrier permeability. The up-regulation of nitric oxide 
(NO) can help mediate and at times eliminate these effects, but it depends on the amount 
of NO and the source [72]. When a moderate concentration of NO is released by eNOS, 
endothelial function will be preserved and inflammation will become inhibited. However, 
if an increased concentration of NO is produced by inducible NOS, found in activated 
inflammatory microglia, reperfusion injury will be augmented. Large amounts of NO 
from inducible NOS cause the formation of the free radical peroxynitrite, which is toxic 
[72]. Hypothermia will impede inducible NOS transcription, allowing for less free radical 
injury [72] 
This NO system can be managed through hypothermia. Lower temperatures have 
a protective effect against reperfusion injury, by preserving the endothelial barrier 
function and calming the inflammation response [72]. The protective effects of 
hypothermia are eNOS dependent and linked to the up-regulation, expression and 
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phosphorylation of eNOS. The up-regulation of eNOS after ischemia may be an intrinsic 
mechanism set off by the low temperature to protect the surrounding tissues [72]. 
Researchers used eNOS knockout and wild-type mice for a left pulmonary hilum 
occlusion surgery. The occlusion lasted for one hour, followed by five hours for 
reperfusion. During the ischemic event, the left pleural cavity was kept at one of two test 
temperatures: 36C (normal) or 32C (hypothermic). Hypothermia triggered an up- 
regulation of eNOS within 5 hours of the ischemic event and an increase in eNOS 
expression within 2 hours of reperfusion [72]. Several mechanisms may account for the 
protective responses observed with induced hypothermia [72]. During a period of 
lowered temperature, cell injury is delayed by the decreasing rate of metabolism. Since 
metabolism is slowed, the cell utilizes very little ATP and lastly ion homeostasis within 
the cell becomes essential [72]. Inducing brain hypothermia, using a “Cool-Cap” is a 
standard treatment for neonatal hypoxia-ischemia (stroke), which can occur during a 
difficult birth. At birth, the skull is thin enough to permit temperatures changes with the 
cool cap, allowing increased functional recovery in neonates. 
During times of oxygen deprivation, eNOS will assist in reducing nitrite to nitric 
oxide. This beneficial property of nitrite is improved in hypoxic environments. Using 
eNOS knockout (KO) mice showed that the reduction of nitrite is mediated by the 
protein, eNOS [73]. Researchers used KO and wild-type mice for the 
ischemic/reperfusion experiment. They applied sodium nitrite topically after 30 minutes 
of ischemia, and allowed reperfusion for 24 hours. The deficits were reduced in wild-type 
mice; however, in KO mice the deficits were increased. Chemiluminescence 
demonstrated quick distribution of the nitrite within one minute of application [73]. 
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Since eNOS is a vasoprotective enzyme, the expression of eNOS poses many 
consequences for vascular homeostasis. Because eNOS is a vasodilator, rats without the 
eNOS gene are hypertensive [74]. If eNOS is inhibited in the brain, embolic processes 
increase vascular resistance. The result is the brain parenchyma becomes more vulnerable 
to injury via ischemia [75]. Mice lacking neural nitric oxide synthase (nNOS) are able to 
resist cerebral ischemia, but this resistance can be turned off by inhibiting eNOS [75]. 
It would be helpful for future treatment if there were a way to artificially express 
eNOS. A study was performed where a recombinant eNOS gene was administered 
perivascularly to adult mongrel dogs of both sexes via CSF so that the cerebral blood 
flow was not disturbed [76]. Administration was performed in vivo and dispensed to the 
adventitia of the cerebral arteries. The eNOS protein was found in the invaginations of 
the plasma membranes. The ventral surface of the brain revealed a higher expression of 
eNOS than the dorsal surface, which was beneficial because the major cerebral arteries 
are located ventrally [76]. The results were exciting because of the manner of 
administration and the functional expression of the gene [76]. 
Drug Delivery Method 
 
Adult neurogenesis is inhibited by stress and depression [60]. These effects have 
been shown experimentally, with not only structural and functional changes in neurons, 
but also alterations in both glucose metabolism and cerebral blood flow [60]. It is common 
practice to utilize intraperitoneal injections (IP) as part of standard protocol due to the ease 
of administration and lack of problems with appropriate dosing. Although the physiological 
response depends on the methods, frequency and duration, indications of stress have been 
found in such trivial situations as weighing, handling and cage cleaning for    individually 
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housed rodents [77]. The consequences manifested as tachycardia and hyperthermia. In 
addition, a type of depressive state was also realized by researchers in 1997 when after 
repeated saline injections the rats became subdued and remained immobile for long periods 
of time [78]. If IP injections skew the overall results, it would behoove us to find methods 
that are more neutral. 
When testing post-stroke medications that might enhance neurogenesis, then, it 
becomes important that we deliver the medication in a manner that reduces stress. After 
trying a variety of substances, we found that sugar cookie dough had the best consistency 
for mixing in the medications and the animals were willing and able to consume the 
entire dough ball. Consuming the vehicle in its entirety was important for standardization 
of the medication doses. There was no stress associated with this method, as the animals 
looked forward to the feeding each day and usually consumed the dough ball with 
medicine within 5 minutes. 
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MATERIALS AND METHODS 
 
Subjects 
 
For experiments both Wistar and Fisher retired breeder rats were utilized. The 
Wistar rats were male, weighing 500-750 grams (Charles River). The Fisher rats were all 
females with the exception of three males, which were part of the control group. The Fisher 
rats weighed 200-300 grams (Harlan). All rats were at least one year old, making this an 
aged animal model, as the normal life expectancy for rats is around 2 years [24]. The Fisher 
rats were used for the oral administration of medication study as well as the gene analysis 
and the Wistar rats were used for the oral administration of medication study and the 
neurogenesis study. Each rat had its own cage before and after surgery and the animal 
protocols were approved by the Wright State University LACUC (Laboratory Animal Care 
and Use Committee). 
Experiment 
 
The subjects were divided into groups that received either a distal middle cerebral 
artery electrocoagulation or a sham surgery. Then these rats were divided into groups that 
were either: control (no treatment), statin treatment, fluoxetine, or fluoxetine and statin 
combination treatment. The rats were further divided into 2 groups of 2-week rats and 1 
group of 5-week rats. (The purpose of the first group of 2-week rats (Wistar) and the 5- 
week rats (Wistar) was to compare the differences that the treatment had on the animals 
over a short period of time vs a long period). The other 2-week rats (Fishers) were sent 
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for a gene analysis to look for any upregulated genes that may be associated with the 
experiment. 
All medication was individually weighed and placed in the middle of small cookie 
dough balls in the following amounts for the Wistar strain: control-no medication, statin 
combination- 0.5mg/kg simvastatin, 20mg/kg l-arginine and 20mg/kg ascorbic acid, 
fluoxetine- 5mg/kg and fluoxetine and statin combination- 5mg/kg. The Fisher rats had 
the same medications in the same amounts minus the 20mg/kg l-arginine in the statin 
combination. The rats were fed their medication once/day beginning 1 day after the 
surgery and continuing for a full two weeks or five weeks as necessary. 
Voluntary Oral Administration of Drug Treatment 
 
We used a variety of different food substances to test, which would work best as 
the vehicle for our drug administration. A standard amount of the substances (4-5 grams) 
were left in each rat’s cage overnight and the next day we would document which foods 
were eaten in entirety. Once we had chosen our treatment vehicle, we needed a 
standardized method of preparation and administration. First, we made dough balls that 
were 4 grams and placed them into 60 mm glass petri dishes. A small indentation was 
made in the middle of each ball and the exact amount of drugs in a fixed dosage (mg/kg) 
for a specific rat (based on individual rat weight) was placed in the cavity. We then 
pinched the sides together and manually mixed the drug treatment into the dough ball, 
placed it back in the glass petri dish and put a plastic weighing boat on top with the rat’s 
identification number. Figure 9A shows the protocol used when preparing the cookie 
dough medicine balls. 
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Figure 9  Cookie dough preparation and a rat consuming the cookie dough ball. 
(A) Cookie dough preparation: 4 grams of dough with a cavity made in the center, drugs placed in 
cavity, fold the sides, mix thoroughly and roll into a ball (B) Rat consuming cookie dough ball 
 
 
It was important to use a glass petri dish because during previous feedings the rats 
had chewed on or eaten part of the plastic petri dishes. In addition, each weigh boat was 
labeled with a rat’s ID number and removed before placing the petri dish in the cage. 
Although most rats consumed the food quickly, some ate a little slower. Knowing 
this, we would leave the dough balls overnight and switch out the petri dishes the next 
day, loaded with fresh cookie dough. In Figure 9B, a Fisher rat is eating the cookie dough 
medicine ball roughly 3 minutes after it was presented to her in the cage. 
We kept track of any uneaten cookie dough to include in our analysis of this new 
approach. Any rat that left part of the medicine was documented, including all controls. 
Reliability of the method was determined using the following equation, which provides a 
percentage of complete ingestion of the drugs: 
Reliability = 1 – (# of incidents of non-ingested drugs) / (#rats) * (# days drugs given) 
 
The rats were given plain sugar cookie dough for 3 days in order to acclimate to 
this new food item. During this 3-day trial, uneaten dough was not counted against 
reliability. 
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Distal Middle Cerebral Artery (MCA) Occlusion 
 
Each rat was anesthetized using 5% isoflurane while inside an induction chamber 
and after 5 minutes the anesthesia was reduced to 2.5-3%. Ointment was applied to the 
eyes of the rats to prevent drying. With the Wistars, the ointment was applied before 
anesthesia but it was applied afterwards with the Fishers (as they were more likely to 
bite). 
Once the subject was under anesthesia, it was moved from the induction chamber 
to the gas mask. A Benchkote mat was placed over a heating pad that was set to 37C and 
the rat was laid on its left side. The right side of the head was shaved and then cleaned 
with Provoiodine, 70% isopropyl alcohol and Provoiodine, respectively. 
A 2cm incision was made between the lateral canthus of the right eye and the 
external auditory meatus. To decrease the pain for the animal upon awakening, 
bupivivaine was applied, drop-wise along the incision. Next, the temporal muscle was 
located, carefully dissected, and retracted so as not to disturb the associated 
neurovascular structures. Once the zygomatic arch was exposed, the approximate location 
of the MCA could be determined. In the Fisher rats, the MCA arose rostral to the fusion 
of the zygomatic arch and more toward the anterior edge. However, in the Wistar rats the 
MCA appeared 2-3 mm anterior to that of the Fisher rats. 
A dental drill was used to make a 4-6 mm hole in the squamosal bone. A cruciate 
incision was made in the Dura using a 22-gauge needle. After the MCA was identified, it 
was electro-coagulated with a bipolar Malus electro-coagulator at several different 
positions, both before and after it branched. Sterile bone wax was used to seal the hole 
and 4-0 Vicryl sutures were used to close the surgery site. The suture line was then 
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coated with Provoiodine. Animals receiving a sham surgery still had the MCA exposed, 
but no electrocoagulation. Unfortunately, after the rats were euthanized, we saw no 
evidence in the brain that this stroke surgery was successful in producing an infarct, 
leading us to treat each animal as a sham stroke surgery and investigating 
pharmacological effects on neurogenesis in the absence of stroke. 
Tissue Collection and Cryosectioning 
 
After full drug treatment of either 2 weeks or 5 weeks had been administered, the 
rats were cardio-perfused. First, each rat was euthanized with an IP injection of 
pentobarbital (150mg/kg) and then cardio-perfused with phosphate buffered saline (PBS) 
to remove the blood. The rat was then cardio-perfused with 4% paraformaldehyde in PBS 
to fix the brain tissue. Afterwards, the brains were carefully removed and cut into coronal 
blocks of forebrain, midbrain, and hindbrain and stored in a 30% sucrose solution until 
time for cryosection and immunohistochemistry. A small cut was made on the ventral 
right side of the brain for quick orientation during microscope analysis. 
Brains were sliced in coronal sections at 50-micrometer thickness using a cryostat 
machine. Each block of brain was placed on a chuck prepped with Optimal Cutting 
Temperature compound (OCT) and then embedded in OCT. The chuck was then placed 
in a Styrofoam container and completely covered with powdered dry ice for 
approximately 10 minutes. The embedded brain tissue was placed in the cryostat machine 
to equilibrate to the appropriate temperature, of -26 to -28 C. This normally took about 
15 minutes and was adjusted depending upon the humidity and temperature of the room 
each day. Fresh razor blades were used to ensure clean cuts, less tissue damage and 
minimal curling. Four scintillation vials filled with PBS were used for each cutting 
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session. A session consisted of collecting 15-20 slices in each vial and continued with 
four more vials until all of the tissue had been sliced. The vials were all labeled 
appropriately with the number of the rodent and part of the brain it contained. 
Immunohistochemistry 
 
Immunohistochemistry was performed using free-floating sections, and the 
Vector Laboratories ABC technique. Protocol was followed per the immunoperoxidase 
system of Vectorlabs (Vector laboratories catalog # SP-2001). The general instructions 
for the ABC method include incubation with a blocking solution containing serum of the 
host of the secondary antibody, application of unlabeled primary antibody, wash and 
application of the biotinylated secondary antibody, wash and application of the preformed 
avidin and biotinylated horseradish peroxidase (HRP) conjugate. Lastly, following the 
final wash, the DAB substrate is added, one of the most common substrates utilized with 
HRP. The free radicals produced by the peroxidase, oxidize DAB and cause it to 
crystallize. This oxidation product amplifies the signal at the antigen sites. To mark areas 
of neurogenesis, a Doublecortin primary antibody was used with a 1:500 concentration. 
ABC Protocol 
 
Tissue sections were incubated with 1% blocking reagent solution overnight at 
4C, in a standard tissue culture six well plate with 5ml solution in each well and the 
tissue inside a netted plastic enclosure (Netwell) that fits in the well while shaking. To 
move the tissue quickly from one plate to another, you simply lift the netted enclosure 
containing the tissue and move it to the next plate containing the appropriate solution. 
Next, the specimen was labeled with the primary antibody, Doublecortin (Cell Signaling 
Technology, Inc. #4604, rabbit). Primary antibody, raised in rabbit, was diluted 1:500 in 
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1% blocking reagent and the tissue was transferred to a new 6-well plate to incubate on 
the shaker for another 60 minutes at room temperature. Before being transferred into the 
third plate of secondary antibody, the tissue went through (2) 10 minute washes with 
PBS-Tween and a third 10-minute wash with HEPES/NaCl. After the washes, sections 
were transferred to wells containing with biotinylated 2 antibody (anti-rabbit) and left on 
the shaker to incubate at room temperature for 2 hours. The tissue was washed again, 
twice for 10 minutes in PSB-Tween and once in HEPES/NaCl. Next, sections were 
transferred to new wells and treated with the macromolecule complex, avidin and 
biotinylated HRP, for the next 30 minutes on the shaker at room temperature. A final 
rinse with PBS was performed before developing with Diaminobenzidine (DAB). The 
DAB working solution was prepared per Vector Laboratories instructions (DAB substrate 
kit for peroxidase, catalog # sk-4100). Specimens were incubated with gentle agitation at 
room temperature until desired staining developed, which was normally 5 minutes or less. 
The slices were washed well to remove any residual DAB and mounted on gel-subbed 
slides, and allowed to dry. Once dried, the slides were dehydrated in a fume hood using 
graded concentrations of ethanol and then xylene. Ethanol baths consisted of 5 minutes 
each in 70%, 95%, 95%, 100%, 100%, and then (2) 5 minute baths in xylene. 
Immediately following dehydration, DPX from Electron Microscopy Sciences was 
applied across the sections and the slide was cover slipped. DPX is a hard mountant, fade 
resistant, quick-drying made of distyrene, a plasticizer and xylene. 
Microscopic Analysis 
 
Slides were analyzed using a bright field microscope. Pictures of the DCX stained 
area of the SVZ were taken of each hemisphere and scale bars were added to assist in 
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later statistical analysis. To analyze the pictures, Image J (NIH) program was used. This 
program allowed the DCX labeled area to be outlined and parameters to be set the same 
for each image so the analysis was consistent. Each hemisphere had the DCX stained area 
in 10 ventricles summed in m2 and converted to mm2 for statistical analysis. 
Statistical Analysis 
 
The treatment groups used for statistical analysis were control, simvastatin and 
ascorbic acid, fluoxetine, and the combination of simvastatin, ascorbic acid and 
fluoxetine. SPSS software was used for each statistical test. A one-way analysis of 
variance (ANOVA) was performed to look for a difference between groups. A 
Bonferroni post-hoc test showed where the differences were for each group. In order to 
check for differences between the right and left sides of the brain, a two-way ANOVA 
was done. To check for differences in weight at two different time points for the four 
drug treatment groups, a repeated measures ANOVA was used. In addition, t-tests were 
also used to check for significant differences between a treatment group and control. 
Gene Analysis 
 
Animals in the gene analysis group underwent the same protocol as the other rats 
with regards to voluntary oral drug administration and distal middle cerebral artery 
occlusion surgery. However, after brain removal, the tissue was quick-frozen in 
isopropanol and dry ice and the frozen cortical samples were sent off to the CGR group, 
at Wright State University, for genetic analysis. They then prepared RNA from the frozen 
tissue, converted this into cDNA using a reverse transcriptase reaction, and then used the 
cDNA to probe the rat gene chip 
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RESULTS 
 
Voluntary Oral Administration of Medication 
 
For our primary study, we wanted to test four different post-stroke treatments for 
their effects on neurogenesis. The drug treatments were control (vehicle), 0.5 mg/kg 
simvastatin plus 20 mg/kg ascorbic acid; 5 mg/kg fluoxetine; or 5 mg/kg fluoxetine plus 
0.5 mg/kg simvastatin plus 20 mg/kg ascorbic acid. 
 
Since these treatments are oral medications by design, it would behoove us to find 
a way to compel the animals to eat them. A challenge to this approach was making sure 
the entire dose of medication was ingested. This required identifying a reliable vehicle for 
administration that the rats would enjoy and consistently ingest in its entirety. 
We tested a variety of foods without medication, on the Wistar rats. We left the vehicles 
in the cages overnight and documented consumption amounts for each. After the data 
were collected for each food, it was determined that Brunschweiger, sugar cookie dough, 
peanut butter cookie dough and chocolate chip cookie dough (Pillsbury) were the most 
successful vehicles. To narrow it down to one substance, we looked at ingredients, price 
and ease to work with. Sugar cookie dough had a simpler ingredient list than the other 
doughs, was cheaper than Braunschweiger and had a great consistency for mixing in the 
dry medications. We also tried two different substances from animal food vendors, Napa 
Nectar and Bio-Serv (transgenic dough), but the rats did not like either of them. Once we 
started using the sugar cookie dough, the animals would normally consume it within 
34  
30 minutes. For consistency purposes, we always left the Petri dishes in their cages 
overnight. 
We utilized this method of medication administration on a total of 79 rats, 24 
Wistar males and 55 male and female Fishers, for a two-week period with considerable 
reliability. There were only 5 times out of these 1106 times the rats were given the 
vehicle or vehicle plus meds in this daily treatment, where an animal did not finish the 
dough ball completely. This is a significantly high success rate of 99.5% (using equation 
1106 complete consumption/1111 total feedings = .9954). The uneaten portions were 
seen in each of the treatment groups, including the control, which leads us to believe it 
was not the taste of the medications that discouraged the animals from finishing. Later, 
16 female Fishers were administered their medication through the same method for 35 
days with a 100% reliability rate. See Table 1. 
Table 1 Drug ingestion reliability. 
Incomplete drug ingestion incidents were noted when more than 100mg of cookie dough were found 
in either the cage or Petri dish from the previous day. 
 
 
 
Rat 
Strain/(gender) 
 
Number of 
Rats 
 
# days of drug 
administration 
Incomplete 
drug ingestion 
incidents 
# of rats with 
incomplete 
ingestion 
 
Reliability 
Wistar (male) 24 14 1 1 99.70% 
Fisher (male and 
female) 
 
55 
 
14 
 
4 
 
3 
 
99.48% 
Fisher (female) 16 35 0 0 100% 
 
 
 
The cookie dough method allowed for a simple and reliable means of 
administering an oral medication to an animal without the nuisance of IP injections or 
unnecessary stress on the rodent. However, the approach came with the added benefit of 
35  
stabilizing the weight of the rats. It is normal for rats to lose 5-10% of their weight after a 
sham stroke surgery and 17-20% after a stroke surgery using middle cerebral arterial 
occlusion [79]. The cookie dough method allowed our rats to lose less weight than 
average, maintain, or gain weight, as described in the next section. 
Fisher Rats 
 
The rats were retired breeders and around 1 year old. The females were from 
Harlan, the three male Fishers were from Charles River, and although we do not have a 
date of birth, we had asked for approximately the same age. Using rats that were a year or 
more older would ensure the animal model represents realistic human scenarios and 
translates well into clinical trials. Weights were recorded pre-surgery and one week post- 
surgery. Using the descriptive statistics in Table 2, a bar graph was created with the pre- 
surgery and post-surgery weight averages. The animals in group 2, receiving the 
fluoxetine treatment, showed a 5% weight loss, or about 15 grams, which is on the low 
end of normal for a sham surgery [79]. Group 3, treated with the fluoxetine combination 
showed an average of 0.6% weight loss, while the other two Fisher rat groups were not 
affected and actually showed a weight gain during the week following surgery. Figure 1 
represents the Fisher rats’ weights, pre-surgery (solid bars) vs. post-surgery (striped bars), 
which were taken one week later. The four different treatment groups are as follows: 
Group 1, vehicle control- Group 2, 5mg/kg fluoxetine -Group 3, 5 mg/kg fluoxetine, 5 
mg/kg simvastatin and 20 mg/kg ascorbic acid -Group 4, 5 mg/kg simvastatin and 20 
mg/kg ascorbic acid. To look for differences between pre-surgery and post-surgery 
among treatment groups, we analyzed the data using ANOVA. The results for this 
ANOVA are shown in Table 3. There is a statistically significant interaction between 
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Factor A (treatment) and Factor B (pre/post-surgery), with an interaction value of p = 
0.002. 
Table 2 Summary statistics for Fisher rats' weights 
 
 
 Control  Fluox  Fluox Combo  Statin Combo  
Pre-Surge ry We ight Post-Surgery We igh Pre -Surgery We ight Post-Surge ry We ight Pre -Surgery We ight Post-Surgery We igh Pre-Surge ry Weight Post-Surge ry We ight 
420 430 417 377 341 339 256 257 
315 320 259 252 290 291 253 256 
250 256 251 241 263 264 256 256 
265 267 251 244 254 245 261 269 
260 270 283 271 279 279 275 273 
282 278 268 256  281 276 
Average 298.667 303.500 288.167 273.500 285.400 283.600 263.667 264.500 
Std 58.114 60.049 58.658 47.282 30.467 31.683 10.546 7.797 
sqrt 2.449 2.449 2.449 2.449 2.236 2.236 2.449 2.449 
s.e. 23.725 24.515 23.947 19.303 13.625 14.169 4.305 3.183 
 
 
 
 
 
 
 
 
Figure 10 Fisher rats' weights before and one week after surgery, divided into treatment 
groups. 
The four different treatment groups are as follows: Group 1, vehicle control- Group 2, 5mg/kg 
fluoxetine- Group 3, 5mg/kg fluoxetine, 5mg/kg simvastatin and 20 mg/kg ascorbic acid- Group 4, 
5mg/kg simvastatin and 20 mg/kg ascorbic acid 
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Table 3 ANOVA Fisher rats' weights. 
There is a statistically significant interaction between Factor A (treatment) and Factor B (pre/post- 
surgery). DF = degrees of freedom, SS = Sum of Squares, MS = Mean Square, F = F statistic, P = p 
value 
 
 
Source of Variation DF SS MS F P 
Factor A 3 8250.55 2750.19 0.606 0.619 
Subject(Factor A) 19 86186.8 4536.15   
Factor B 1 85.906 85.906 2.919 0.104 
Factor A x Factor B 3 635.807 211.936 7.202 0.002 
Residual 19 559.15 29.429   
Total 45 95721.3 2127.14   
 
 
Given the interaction between Factors A (treatment) and B (time) (p = 0.002), the 
Holm-Sidak method was the post-hoc test used to assess all pairwise comparisons. Table 
4 shows these statistics. There was no significance between any of the comparisons, 
except the interaction between Factor B (pre and post-surgery weights) within the 
fluoxetine treatment group (unadjusted p < 0.001). I showed evidence in the Introduction 
that fluoxetine treatment often leads to weight loss. 
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Table 4 Fisher: Holm-Sidak post-hoc method for multiple comparisons. 
There was no significance between any of the comparisons, except the interaction between Factor B 
within the fluoxetine treatment (unadjusted p < 0.001). 
 
 
Factor B within Control      
Comparison Diff of Means t Unadjusted P Critical Level Significant 
Post vs. Pre 4.833 1.543 0.139 0.050 NO 
      
Factor B within Fluox      
Comparison Diff of Means t Unadjusted P Critical Level Significant 
Post vs. Pre 14.667 4.683 <0.001 0.050 YES 
      
Factor B within Fluox combo      
Comparison Diff of Means t Unadjusted P Critical Level Significant 
Post vs. Pre 1.8 0.525 0.606 0.050 NO 
      
Factor B within Statin      
Comparison Diff of Means t Unadjusted P Critical Level Significant 
Post vs. Pre 0.667 0.213 0.834 0.050 NO 
      
Factor A within Pre      
Comparison Diff of Means t Unadjusted P Critical Level Significant 
Control vs. Statin 34.833 1.263 0.222 0.009 NO 
Fluox vs. Statin 24.333 0.882 0.389 0.010 NO 
Fluox Combo vs. Statin 21.567 0.745 0.465 0.013 NO 
Control vs. Fluox Combo 13.267 0.459 0.652 0.017 NO 
Control vs. Fluox Combo 10.5 0.381 0.708 0.025 NO 
Fluox vs. Fluox Combo 2.767 0.0956 0.925 0.050 NO 
      
Factor A within Post      
Comparison Diff of Means t Unadjusted P Critical Level Significant 
Control vs. Statin 39.000 1.414 0.173 0.009 NO 
Control vs. Fluox 30.000 1.088 0.29 0.010 NO 
Control vs. Fluox Combo 19.900 0.688 0.5 0.013 NO 
Fluox Combo vs. Statin 19.100 0.66 0.517 0.017 NO 
Fluox Combo vs. Fluox 10.100 0.349 0.731 0.025 NO 
Fluox vs. Statin 9.000 0.326 0.748 0.050 NO 
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Wistar Rats 
 
The male Wistar rats, which came from Charles River, weighed 500-750 grams. 
This 250-gram range accounts for much of the range in the error bars. We do not have a 
date of birth for these rats, but they were retired breeders and we requested rats 10-12 
months old when we ordered them. Unlike the Fisher rats, the Wistar’s post-surgery 
weights were compared at one week and two weeks with summary statistics found in 
Table 4. The Wistar rats in group 4 received the statin combo treatment and lost the most 
weight the first week after surgery with an average of 14g or 2.3%. The second week they 
began to regain the weight. Groups 1 (control) and 3 (Fluoxetine combo treatment) lost 
10.83g and 10.66g, respectively, in the first week. In the second week, the control group 
began to regain the weight, however group 3 lost a little more. The total amount of 
weight lost in group 3 averaged 13.6g that is only 2% and appreciably below the average 
range of 5-10%. Group 2 (Fluoxetine treatment) had the least weight loss at 0.5% (3.5g) 
on average and began to regain the weight in the second week after surgery. A bar graph 
of these weight averages can be found in Figure 11. The solid bars indicate pre-surgery 
weights, while the striped bars represent 1-week post-surgery and the crossed bars are 2 
weeks post-surgery. 
Table 5 Summary statistics for Wistar rats' weights 
 
 Control Fluox Fluox Combo Statin Combo 
 pre post post pre post post pre post post pre post post 
 734 718 720 724 723 716 687 660 661 552 550 545 
 680 656 665 635 635 643 675 665 662 750 730 733 
 702 690 699 549 535 543 629 623 616 686 675 674 
 599 595 604 642 636 640 586 592 592 592 570 576 
 585 583 581 524 513 520 698 694 685 527 525 530 
 515 508 519 629 640 651 642 619 619 536 509 520 
Average 635.830 625.000 631.330 617.170 613.670 618.833 652.830 642.170 639.170 607.170 593.170 596.330 
Std 75.836 70.932 70.087 65.593 70.620 67.115 38.408 34.027 32.318 83.047 81.190 79.567 
sqrt 2.449 2.449 2.449 2.449 2.449 2.449 2.449 2.449 2.449 2.449 2.449 2.449 
s.e. 30.960 28.958 28.613 26.778 28.831 27.400 15.680 13.891 13.194 33.904 33.146 32.483 
40  
 
 
Figure 11 Wistar rats' weights before surgery, one week post, and two weeks post-surgery. 
The four different treatment groups are as follows: Group 1, vehicle control- Group 2, 5mg/kg 
fluoxetine- Group 3, 5mg/kg fluoxetine, 5 mg/kg simvastatin and 20 mg/kg ascorbic acid- Group 4, 
5mg/kg simvastatin and 20 mg/kg ascorbic acid. 
 
 
In order to check for differences and interactions among treatments and weights, a 
Repeated Measures ANOVA, comparing treatment groups (Factor A) with pre-surgery 
weight, one week post-surgery weight and two weeks post-surgery weight, indicates that 
there is a significant difference in the mean values among the different levels of Factor B 
(weights over time) (p < 0.001). This is shown in Table 6. To distinguish which groups in 
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Factor B were significantly different from one another, we ran a post-hoc test for multiple 
comparisons, using the Holm-Sidak Method, once again. In Table 7, you can see the 
results from this test. 
After making all pairwise comparisons between pre/post-surgery weights, 
independent of treatment, it was found that the pre-weights were significantly different 
from the post weights in both week one (unadjusted p < 0.001) and two (unadjusted p < 
0.001). However, post-surgery weights in weeks one and two did not differ significantly 
from each other. 
Table 6 A repeated measures ANOVA, Wistar rats' weights. 
The repeated measures ANOVA, comparing pre-surgery weights to one-week post-surgery and again 
to weights two weeks post-surgery. Factor A is treatments, while Factor B is pre/post-surgery 
weights. DF = degrees of freedom, SS = Sum of Squares, MS = Mean Square, F = F statistic, P = p 
value There is a significant difference in the mean levels of Factor B (p < 0.001). 
 
Source of 
Variation 
DF SS MS F P 
Factor A 3 20773 6924.33 0.438 0.728 
Subject 
Factor A 
20 316384 15819.2 
  
Factor B 2 1202.11 601.056 15.708 <0.001 
Factor A x 
Factor B 
6 502.667 83.778 2.189 0.064 
Residual 40 1530.56 38.264   
Total 71 340392 4794.26   
42  
Table 7 Wistar: Holm-Sidak for multiple comparisons. 
Factor B, pre/post surgeries, (significance level 0.05); Independent of treatment, the pre-weights were 
significantly different from the post weights in both week one (unadjusted p < 0.001) and two 
(unadjusted p < 0.001). 
 
 
Comparisons for Factor B      
Comparisons Diff of Means t Unadjusted P Critical Level Significant 
Pre vs. Post 1 9.75 5.46 <0.001 0.017 YES 
Pre vs. Post 2 6.833 3.827 <0.001 0.025 YES 
Post 2 vs. Post 1 2.917 1.633 0.110 0.05 NO 
 
 
The weight comparison between pre and post-surgery was important to analyze 
because weight has been a long-standing parameter associated with health in laboratory 
experiments [80]. As shown in the table below, the largest weight loss across all 
treatments was still at the low end of the normal range of 5-10% for sham surgeries. All 
other weight loss was below this normal range. 
Table 8 Fisher rats and Wistar rats total weight loss with each treatment. 
 
FISHER 
 
CONTROL Not affected: weight gain week following surgery 
FLUOX 15g loss: 5%: low end of normal for sham 
FLUOX + 0.6% loss: considerably below average 
STATIN Not affected: weight gain week following surgery 
WISTAR 
 
CONTROL 10.83g loss: Weight gain week 2 
FLUOX 3.5g loss: 0.5%: Weight gain week 2 
FLUOX + 13.6g loss total: 2%: below average loss 
STATIN 14g loss: 2.3%: Weight gain week 2 
 
 
 
 
Doublecortin Expression in SVZ Indicative of Neurogenesis 
The primary interest of this study was the effect of three different drug treatments 
on neurogenesis after induced stroke through distal MCAO, in aged rodents. After 
examining the brains post-surgery, we were unable to find any evidence of large brain 
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infarcts, so it was apparent the distal MCA had not been occluded successfully. We 
therefore treated all of the surgery animals as sham stroke surgery animals. This study 
changed to investigate the effects of these treatments on neurogenesis and gene 
expression on sham stroke surgery animals. Fluoxetine (5mg/kg), simvastatin (0.5 
mg/kg) plus ascorbic acid (20 mg/kg) and a combination treatment of fluoxetine, 
simvastatin and ascorbic acid (5mg/kg, 0.5mg/kg, 20mg/kg, respectively) were tested 
against control (no treatment). 
For two weeks, male Wistar rats, which were at least 1 year old, were 
administered one of these drug treatments or control, utilizing the cookie dough method. 
All rats voluntarily ingested their cookie dough balls. To measure neurogenesis we used a 
Doublecortin antibody to stain newborn, migrating neurons in the anterior lateral 
ventricles of the subventricular zone (SVZ) and a horseradish peroxidase labeled 
secondary antibody, using DAB as a substrate. We used images taken with a bright field 
microscope equipped with a digital SPOT camera to view the neurogenesis accentuated 
by the Doublecortin/DAB staining. The visual results of this staining can be seen on the 
tissue sections in Figure 12, while the summary statistics for the mean area of 
neurogenesis with hemispheres combined, is shown in Table 9. In Figure 12, it is visually 
apparent that the largest and most dense area of neurogenesis existed in the 
fluoxetine/statin/ascorbic acid combination treatment group. 
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Figure 12 Neurons in the lateral ventricles of the subventricular zone, stained with Doublecortin 
antibody. 
There is a tiny increase in neurogenesis from control (panel A) following treatment with simvastatin 
(panel B). In panel C is the 11-fold increase in mean area of staining with Doublecortin after 
treatment with fluoxetine. The largest increase can be seen in panel D, representing the 19-fold 
increase in area of staining after the combination treatment fluoxetine, simvastatin and ascorbic acid. 
 
 
 
 
Table 9 Summary statistics for the mean area of neurogenesis in mm2 
 
 
 
Using the summary statistics from Table 9, we created a histogram with the mean area 
of neurogenesis. This graph, Figure 13, demonstrates that the biggest difference in mean 
area of neurogenesis occurred following treatment with the drug combination of 
fluoxetine, simvastatin and ascorbic acid. Comparing the fluoxetine group with control, 
we observed an 11-fold increase in neurogenesis and when comparing the statin group 
with control, there was a 1.4 fold change. The most significant finding was the 19-fold 
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increase in mean area of neurogenesis that we found with the fluoxetine combination 
treatment when compared to control. 
 
 
 
Figure 13 Histogram showing the mean area of neurogenesis for each treatment with hemispheres 
combined. 
When comparing the means of the control group and the fluoxetine treatment group, we note a 10- 
fold change in the mean area of neurogenesis. The most significant result was the comparison 
between the control group and the fluoxetine combination treatment group with a noteworthy 19- 
fold increase in neurogenesis. 
 
We tried to run a one-way analysis of variance with the hemispheres combined, 
using data in mm2, but the Shapiro-Wilk normality test (p<0.050) as well as the equal 
variance test (p<0.050) failed. In order to analyze the data, we ran a Kruskal-Wallis one- 
way analysis of variance on ranks. The results for this one-way ANOVA for treatments 
on combined hemispheres are summarized in Table 10. The differences in the median 
values among the treatment groups were greater than expected by chance and statistically 
significant. The H statistic = 12.734 with 3 degrees of freedom (p = 0.005). A Dunn’s 
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multiple comparisons test, shown in Table 11, isolated the fluoxetine combination group 
vs control as statistically significant (p < 0.05). 
Table 10 Kruskal-Wallis one-way ANOVA for combined hemispheres. 
Median area of neurogenesis stained by Doublecortin measured in mm2. H = 12.734, with 3 degrees of 
freedom (p = 0.005). The ‘N’ is the number of animals in each group. Each animal represents 
summed staining in 10 coronal slices from the SVZ for each hemisphere. 
 
 
Group N Missing Median 25% 75% 
Control 3 0 0.0489 0.042 0.0615 
Statin 4 0 0.0769 0.0574 0.0812 
Fluoxetine 5 0 0.579 0.0491 0.652 
Fluoxetine 4 0 1.015 0.642 1.246 
 
 
 
Table 11 All pairwise multiple comparison procedures using Dunn’s Method. 
The Fluoxetine combination group vs Control was significant, p < 0.05. 
 
 
Comparison Diff of Ranks Q P < 0.05 
Fluox combo vs  Control 11.417 3.14 Yes 
Fluox Combo vs  Statin 8.5 2.525 No 
Fluox Combo vs  Fluoxetine 3.15 0.986 Did not test 
Fluoxetine  vs Control 8.267 2.378 No 
Fluoxetine  vs Statin 5.35 1.675 Did not test 
Statin vs Control 2.917 0.802 Did not test 
 
 
We analyzed these results again with the same tests, but this time but the data 
were given in µm2. Tables 12 and 13 show these results. The H statistic changed from H 
= 12.734 with 3 degrees of freedom (p = 0.005) to H = 14.029 with 3 degrees of freedom 
(p = 0.003). The differences in medians among treatment groups were still greater than 
expected by chance. However, when looking at Dunn’s Method in Table13, there are two 
groups identified as statistically significant: Fluoxetine combination vs. Control and 
Fluoxetine combination vs. Statin (p < 0.05). By increasing the range of numbers being 
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analyzed when we moved from mm2 to um2, we added sensitivity to the statistical 
analysis. 
Table 12 Kruskal-Wallis one-way ANOVA for combined hemispheres. 
Median area of neurogenesis stained by Doublecortin measured in µm2. H = 14.029, with 3 degrees of 
freedom (p = 0.003). The ‘N’ is the number of animals in each group. Each animal represents 10 
coronal slices from the SVZ for each hemisphere. 
 
 
Group N Missing Median 25% 75% 
Control 3 0 48875.670 42022.610 61409.850 
Statin 4 0 76585.865 62737.952 92530.747 
Fluoxetine 5 0 590493.800 528371.200 613099.350 
Fluox 
Combo 
4 0 939336.700 731882.850 1212541.625 
 
 
 
Table 13 All pairwise multiple comparison procedures for combined hemispheres using Dunn’s 
Method. 
The Fluoxetine combination group vs Control was significant, p < 0.05 in addition to Fluoxetine 
combination group vs Statin group, p < 0.05. 
 
 
Comparison Diff of Ranks Q P < 0.05 
Fluoxetine + vs Control 12.5 3.438 Yes 
Fluoxetine + vs Statin 9 2.673 Yes 
Fluoxetine + vs Fluoxtine 4.5 1.409 No 
Fluoxetine vs Control 8 2.301 No 
Fluoxetine vs Statin 4.5 1.409 Did not test 
Statin vs Control 3.5 0.963 Did not test 
 
 
Next, we analyzed the results by hemisphere. The summary statistics in mm2, 
separated by hemisphere, can be found in Table 14. These data failed the Shapiro-Wilk 
normality test (p < 0.050) and the equal variance test (p < 0.050). In order to look for a 
difference among the means of these data, a two-way analysis of variance was calculated 
(Table 15) utilizing the Kruskal-Wallis Method. Factor A represents the different 
treatment groups and the results indicate a significant difference among the groups with p 
< 0.001. This two-way ANOVA also tested the difference in mean values with respect to 
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hemispheres (Factor B) and concluded that there is not a statistically significant 
difference (p = 0.408). The results for the interaction between the two factors, treatment 
and hemisphere, showed no statistical significance (p = 0.866). 
To isolate the differences among the treatment groups (Factor A) a multiple 
comparisons test was performed. The Holm-Sidak method was used with an overall 
significance level of 0.05. All comparisons for Factor A can be seen in Table 16. The 
only group found to be not statistically significant was the statin vs. control (unadjusted p 
= 0.826). The other five comparisons were all found to be significant with unadjusted p 
values < 0.001. A graph of each treatment group, separated into hemispheres, can be seen 
in Figure 14. 
Table 14 Summary statistics of area, separated by hemisphere, measured in mm2 
 
Group Side Mean N Std. Deviation Min Max 
Control 
Left 
Right 
0.027 
0.024 
3 
3 
0.007 
0.006 
0.019 
0.018 
0.031 
0.031 
Statin 
Left 
Right 
0.035 
0.037 
4 
4 
0.013 
0.008 
0.021 
0.030 
0.051 
0.045 
Fluoxetine 
Left 
Right 
0.264 
0.308 
5 
5 
0.041 
0.075 
0.215 
0.194 
0.327 
0.370 
Fluoxetine  Combo 
Left 
Right 
0.453 
0.515 
4 
4 
0.141 
0.179 
0.274 
0.299 
0.600 
0.668 
49  
Table 15 Two-Way ANOVA for separated hemispheres using the Kruskal-Wallis Method. 
Factor A is treatments, Factor B represents hemispheres. DF = degrees of freedom, SS = Sum of 
Squares, MS = Mean Square, F = F statistic, P = p value. There is a significant difference among 
means of the treatment groups, p< 0.001. 
 
Source  of Variation DF SS MS F P 
Factor A 3 1.098 0.366 47.263 < 0.001 
Factor B 1 0.005 0.005 0.708 0.408 
A x B 3 0.006 0.002 0.243 0.866 
Residual 24 0.186 0.008   
Total 31 1.297 0.042   
 
 
Table 16 Holm-Sidak method for multiple comparisons on separated hemispheres for Factor A, 
Treatment 
 
Comparison 
Diff of 
Means 
t 
Unadjusted 
P 
Critical 
Level 
Significant? 
Fluox Combo vs Statin 0.448 10.18 <0.001 0.009 YES 
Fluox Combo vs Control 0.458 9.644 <0.001 0.01 YES 
Fluoxetine vs Statin 0.25 5.998 <0.001 0.013 YES 
Fluoextine vs Control 0.261 5.742 <0.001 0.017 YES 
Fluox Combo vs Fluoextine 0.197 4.729 <0.001 0.025 YES 
Statin vs Control 0.0106 0.222 0.826 0.05 NO 
 
 
Figure 14 Mean area of neurogenesis separated by hemisphere and treatments. 
 
Seventy-nine rats were treated with Fluoxetine (5mg/kg), simvastatin (0.5 mg/kg) plus ascorbic acid 
(20 mg/kg), a combination treatment of fluoxetine, simvastatin and ascorbic acid (5mg/kg, 0.5mg/kg, 
20mg/kg, respectively) or no treatment (control). After MCA occlusion, neurogenesis was measured 
by staining newborn, migrating neurons with Doublecortin. Since there was no infarct induced, there 
is no significant difference shown between the hemispheres. 
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Gene Analysis Results 
 
Neither Simvastatin nor Fluoxetine were originally designed to increase 
neurogenesis. It is likely that these drugs are working in a way outside of their normal 
mechanism of action and something about the combination of the simvastatin and 
Fluoxetine caused a synergistic increase in neurogenesis. In order to determine how these 
drugs may have been working in the brain, we isolated cortical tissue from animals with 
each of the drug treatments, rapidly froze the tissue and provided it to the Genomics 
Research Center for analysis of gene expression using the Rat Gene Chip. We provided a 
large portion of the cortex and allowed the Genomics Research Center to choose a 
smaller portion to analyze. In hindsight, we now know that we should have concentrated 
on regions near the Subventricular zone of the Lateral Ventricles, as growth factors are 
concentrated in this region. We would have seen more gene changes with respect to these 
growth factors if we had isolated the subventricular zone for analysis. Dr. Markey 
isolated RNA from the tissue, then used this RNA to reverse transcribe cDNA. Rat Gene 
Chips were probed with the cDNA of the different treatment groups. Performing the gene 
chip analysis allowed us to leverage the wealth of knowledge available to researchers in 
the Gene Ontology database. This automated analysis helps to identify patterns within 
groups of genes and to ascribe a biological meaning to the expression. Correlating 
biological meaning with specific genes or gene groups and combing that knowledge with 
experimental research allows scientists to make inferences that are well-supported about 
possible mechanisms of action that support the increase in neurogenesis. Unfortunately, 
we performed this experiment in the early days of gene chip analysis and the software 
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could not identify specific genes unique to each drug treatment compared to control. We 
were limited to analysis tools available at that time, which gave us incomplete data. 
A microarray Gene Ontology analysis was performed to identify genes that were 
up-regulated and down-regulated with respect to each of the treatments. These genes 
become of particular importance because if we can manage them through various 
treatments we are closer to mitigating the response to trauma. Expression results in 
entirety can be found in Appendix A. 
The microarray analyses uncovered 14 up-regulated genes (>2 fold change, 
p<0.05) in fluoxetine treatment versus vehicle. There were 5 up-regulated genes (>2 fold 
change, p<0.05) in Fluoxetine combination treatment versus vehicle. We found 31 up- 
regulated genes (>2 fold change, p<0.05) in statin/ascorbic acid treatment versus vehicle, 
and 30 down-regulated genes (>2 fold change, p<0.05) in fluoxetine combination 
treatment versus statin/ascorbic acid treatment (Table 17-20). 
Within the fluoxetine treatment versus vehicle, profiling of the up-regulated genes 
showed genetic themes largely involved in molecular functions for channel activity (10 
genes, p<0.05). Genetic themes largely involving biological processes and reactions for 
clotting activity (5genes, p<0.05) were found when profiling the up-regulated genes for 
the fluoxetine combination treatment versus vehicle. When profiling was done for the 
statin/ascorbic acid treatment versus vehicle, there were 31 up-regulated genes showing 
the largest genetic trend towards the biological process for immune response (14 genes, 
p<0.05). Other genetic themes included cascades, signaling and pathways. In the 
fluoxetine combination treatment versus statin/ascorbic acid treatment profiling analysis 
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revealed a trend towards biological process for immune response (19 genes, p<0.05) 
within a group of 30 down-regulated genes (Table 17-20*). 
Gene Ontology Analyses 
 
There are many ways to analyze gene results, however since our most significant 
results came from the two fluoxetine treatment groups, we looked at the data within these 
groups for comparison. Transcription factors are regulators of gene expression. Some 
interesting gene ontology results were found when transcription factor targets were 
merged and analyzed. Both the fluoxetine versus vehicle and the fluoxetine combination 
treatment versus vehicle targeted gene sets for Foxa1 (forkhead box A1), also called 
HNF-3a (hepatocyte nuclear factor 3 alpha) and Hif1a (Hypoxia inducible factor 1a) (up- 
regulated >2 fold change, p<0.05). In the discussion, we will show that Hypoxia 
inducible factor has been regulated by Fluoxetine in other animals following stroke, so 
the changes here are not unprecedented. These genes were produced by interactions of 
the U2 and U6 small nuclear RNA segments of the nuclear spliceosome either 
exclusively or with Transthyretin (Ttr) Table 21. 
When we examined the results of the simvastatin/ascorbic acid treatment group 
versus vehicle we found that the differentially expressed genes up-regulated with a >2 
fold change (p<0.05) belonged to mostly to the ontology of biological processes. Most 
importantly, the biological processes are involved in transport, regulation and response 
shown in Table 22. 
Within this same comparison, the simvastatin/ascorbic acid treatment group 
versus vehicle, we identified the differentially expressed genes, Alpha-2-macromolecule 
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(A2m), protein kinase delta (Prkcd), Sclerostin Domain Containing 1 (Sostdc1), which 
are common to a variety of signaling pathways, shown in Table 23. 
Table 17 . Fluoxetine Treatment vs. Vehicle, genes upregulated >2 fold, p<0.05. 
Genetic trend towards channel activity* 
 
GO Term ID Term type Term name p-value 
35068 CC micro-ribonucleoprotein complex 1.65E-02 
22803 MF passive  transmembrane  transporter activity 2.96E-02 
15267 MF *channel activity 2.96E-02 
22836 MF *gated channel activity 3.43E-02 
22832 MF *voltage-gated  channel activity 2.14E-02 
22838 MF *substrate-specific  channel activity 2.02E-02 
5216 MF *ion channel activity 1.66E-02 
22839 MF *ion gated  channel activity 3.43E-02 
5244 MF *voltage-gated  ion channel activity 2.14E-02 
5261 MF *cation channel activity 2.48E-02 
22843 MF *voltage-gated  cation channel activity 3.81E-03 
8332 MF *low voltage-gated  calcium channel activity 1.83E-04 
KEGG:04020 ke Calcium signaling pathway 2.75E-03 
KEGG:04930 ke Type II diabetes mellitus 8.46E-03 
 
 
 
 
Table 18 Fluoxetine Combination Treatment vs. Vehicle, genes upregulated >2 fold, p<0.05. 
Lowest p-values for genetic trend are biological processes for cell fate roles* 
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Table 19 Statin/Ascorbic acid Treatment vs. Vehicle, genes upregulated >2 fold, p<0.05. 
Genetic trend towards biological processes associated with immunity* 
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Table 20 Fluoxetine Combination Treatment vs. Statin/Ascorbic acid Treatment, genes down- 
regulated >2 fold, p<0.05. Genetic trend of biological processes for immunity* 
 
 
 
Table 21 Fluoxetine vs Vehicle and Fluoxetine Combination vs Vehicle Treatment group, merged 
transcription factor targets up-regulated 2 fold, p<0.05. 
 
Treatment Group Gene Set Gene Symbol  
Fluox vs Vehicle Foxa1 U2|U6 U2 spliceosomal RNA|U6 spliceosomal RNA 
Fluox vs Vehicle Hif1a U2|U6 U2 spliceosomal RNA|U6 spliceosomal RNA 
Fluox Combo vs vehicle Foxa1 Ttr|U2|U6 Transthyetin|U2 spliceosomal RNA 
Fluox Combo vs vehicle Hif1a U2|U6 U2 spliceosomal RNA|U6 spliceosomal RNA 
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Table 22 Gene ontology of Simvastatin/Ascorbic acid Treatment group vs. Vehicle, >2 fold change, p 
< 0.05. 
 
 
 
Table 23 Upregulation 2.0 fold change, in Simvastatin/Ascorbic acid Treatment group versus 
Vehicle. 
The differentially expressed genes are identified as A2m, Prkcd, Sostdc1, looking at common 
pathways, p < 0.05 
 
Gene-Set Name Gene Symbols 
mTOR signaling pathway A2m|Prkcd|Sostdc1 
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling A2m|Prkcd|Sostdc1 
Signaling events mediated by focal adhesion kinase A2m|Prkcd|Sostdc1 
S1P1 pathway A2m|Prkcd|Sostdc1 
PDGFR-beta signaling pathway A2m|Prkcd|Sostdc1 
Internalization of ErbB1 A2m|Prkcd|Sostdc1 
Insulin Pathway A2m|Prkcd|Sostdc1 
ErbB1  downstream signaling A2m|Prkcd|Sostdc1 
EGF receptor (ErbB1) signaling pathway A2m|Prkcd|Sostdc1 
Class I PI3K signaling events mediated by Akt A2m|Prkcd|Sostdc1 
Class I PI3K signaling events A2m|Prkcd|Sostdc1 
Arf6 trafficking events A2m|Prkcd|Sostdc1 
Arf6 signaling events A2m|Prkcd|Sostdc1 
Arf6 downstream pathway A2m|Prkcd|Sostdc1 
EGFR-dependent Endothelin signaling events A2m|Prkcd|Sostdc1 
IGF1 pathway A2m|Prkcd|Sostdc1 
IL5-mediated signaling events A2m|Prkcd|Sostdc1 
GMCSF-mediated signaling events A2m|Prkcd|Sostdc1 
PDGF receptor signaling network A2m|Prkcd|Sostdc1 
Signaling events  mediated by Hepatocyte Growth Factor Receptor (c-Met) A2m|Prkcd|Sostdc1 
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DISCUSSION 
 
Voluntary Oral Administration of Medication 
 
The most uncomplicated method of giving animals their drug treatments is hiding 
the medication in a food or liquid. Currently, the most popular methods of administration 
are oral gavage, IP injections and IM injections, depending upon the medication and 
study [81]. Finding a better solution would benefit the scientific community, as it would 
reduce stress in the animal model in administration of daily medicines. 
The gavage procedure involves manually restraining a conscious animal, insertion 
of a small tube down the esophagus into the stomach and administration of the treatment 
drug into the tube via syringe [82]. This procedure brings with it many issues as each step 
in the process can induce stress in the animal. The stress response is linked to the plasma 
corticosterone (pCORT) level and it has been shown that this measurement parallels the 
animals heart rate during/after it has been subjected to the stressor [83]. Stressors for the 
rodent have been recognized as different types of restraint, injections, cage cleaning and 
excessive handling [83]. These stressors have also been shown to span both male [84] 
and female [85] populations. Results from a study analyzing stress related to oral gavage 
in 2005, showed that the stress response related to the procedure could last for 30-60 
minutes afterwards [86]. 
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Intraperitoneal injections necessitate restraining of the animal, belly-up and 
delivering the medication directly into the peritoneum via syringe. This method is not 
perfect, as the success rate depends highly upon precision. For instance, it is common 
forsome of the treatment to be delivered into the gut, subcutaneous tissue or belly fat, 
therefore the full dose of medicine would not be delivered to the animal’s circulation 
[87]. 
Giving an intramuscular injection can be tricky because the muscle mass is so 
small in rodents and the animal will need to be well restrained. Because of their small 
size, rodents can usually only receive treatments of 0.05ml or less. Additionally, 
discomfort can be caused by injecting material that is not body temperature or has too 
high/low of a pH [87]. 
A study focusing on both IM and IP injections by Morton et al 2001 showed that 
the pattern of heart rate recovery following both types of injections indicated that IP 
injections were more stressful than IM injections and likely, more painful [88]. Variables 
such as technician experience, volume, temperature of the fluid and pH make it difficult 
to standardize these processes [83]. 
Due to the many nuances associated with these most popular methods, 
investigators have researched voluntary oral administration alternatives. In 2002, 
scientists tried using pre-mixed drug chocolate pellets and while they found this method 
effective for use with a large number of rats over an extended period, there were several 
drawbacks [89]. The theobromine and caffeine contained in the mixture may not be 
conducive to mixing with certain drugs or could interfere with the study results. In 
addition, the drug of choice must possess the proper consistency for mixing with the 
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chocolate and the taste should be somewhat disguised to the animal [89]. In our protocol, 
the fluoxetine was still bitter in the mixture, but it seemed that the animals enjoyed the 
cookie dough enough to fully consume the dosage in spite of it. 
Other scientists have tried sucrose solutions with neuroleptic drugs [90] given to 
the animals by syringe which they drank from voluntarily as well as sucrose solutions 
with donepezil and galantamine used for the treatment of Alzheimer disease [82]. 
Although scientists have been able to get the animals to drink voluntarily from the 
syringe, there are limitations associated with the practice. For example, there is a learning 
curve of roughly 3 days to teach the animals. Likewise, the actual procedure itself can be 
time-consuming especially if you are utilizing a large number of animals in the study. 
Only specific medications can be dispensed this way because some do not dissolve into 
solution and may have to be administered in suspension [82]. 
We have demonstrated a reliable method for laboratory rats to voluntarily ingest a 
fixed dose of dry drug treatment. We delivered individually measured dry drugs inside of 
a 4 gm ball of sugar cookie dough daily to our animals. This approach addresses the 
plethora of shortcomings found in previous studies: 
1. The learning curve: Rats enjoyed the sugar cookie dough vehicle so much, they 
were immediately drawn to it 
2. Disguising the taste: Fluoxetine is very bitter and the taste of the cookie dough 
was enough to make them continue eating it 
3. Inability to use suspension medications: Most suspension medications can be 
administered in dry form 
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4. Time-consumption due to lengthy interaction with each animal: With our method, 
the animal does not need to be supervised during administration. 
With stress being such a significant factor in the past, we wanted to find a way to 
overcome that. Because our drug delivery occurred in the animals’ own cage and there 
was no handling or restraint necessary, the animals looked forward to their treatments. 
The rats were housed individually to be sure they ingested their entire dose of 
medication, removing variability in the data due to pain and or stress. Additionally, we 
showed that this dosing could be performed over an extended period, up to 5 weeks in 
this case, and with both Wistar and Fisher strains of rat. A disadvantage to utilizing the 
Cookie Dough Method would be the unsuitability for a diabetic rat model. 
The second component to the oral dosing study was monitoring the weight of the 
animals. Since weight maintenance is regularly associated with health in laboratory 
experiments, it was a goal of ours to design a drug treatment method that would allow the 
animals to remain calm enough to eat regularly and not lose weight during the study. As 
shown in the results, in Table 8, the weight loss of our animals was at the low end of 
normal (5-10% for sham surgeries) or smaller. 
Overall, we believe we have found an effective and reliable method to administer 
drug treatments to two different strains of rats over a prolonged period, of up to 5 weeks 
that eliminates the stress and time-consuming processes associated with IP and IM 
injections and oral gavage. 
Doublecortin Expression in SVZ Indicative of Neurogenesis 
 
We compared the three chosen drug treatments with control, after surgery, but in 
the absence of stroke. Before the surgeries, we performed functional tests using the 
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modified Neurological Severity Score, Table 24 [91] and collected baseline data, which 
did not differ from the data collected after the surgeries. It was the combination of these 
data and the lack of an infarct seen after brain dissection that required us to examine the 
impact of our drug treatments exclusive of stroke, treating all animals as sham surgery 
animals. 
Table 24 Scoring for the mNSS test. 
The higher the score, the worse the deficit is. Our baseline data did not differ from the data we collected after 
the surgeries, indicating that there was no functional deficit. 
Neurological Severity Scores (NSS) 
 Points 
Motor tests  
Raising rat by the tail 3 
1 Flexion of forelimb  
1 Flexion of hindlimb  
1 Head moved >10° to vertical axis within 30 s  
Placing rat on the floor (normal=0; maximum=3) 3 
0 Normal walk  
1 Inability to walk straight  
2 Circling toward the paretic side  
3 Fall down to the paretic side  
Sensory tests 2 
1 Placing test (visual and tactile test)  
2 Proprioceptive test (deep sensation, pushing the paw 
against the table edge to stimulate limb   muscles) 
 
Beam balance tests (normal=0; maximum=6) 6 
0 Balances with steady posture  
1 Grasps side of beam  
2 Hugs the beam and one limb falls down from the beam  
3 Hugs the beam and two limbs fall down from the 
beam, or spins on beam (>60 s) 
 
4 Attempts to balance on the beam but falls off (>40 s)  
5 Attempts to balance on the beam but falls off (>20 s)  
6 Falls off: No attempt to balance or hang on to the 
beam (<20 s) 
 
Reflexes absent and abnormal movements 4 
1 Pinna reflex (head shake when touching the auditory 
meatus) 
 
1 Corneal reflex (eye blink when lightly touching the 
cornea with cotton) 
 
1 Startle reflex (motor response to a brief noise from 
snapping a clipboard paper) 
 
1 Seizures,  myoclonus, myodystony  
Maximum points 18 
One point is awarded for the inability to perform the tasks or for the 
lack of a tested reflex; 13 to 18 indicates severe injury; 7 to 12, 
moderate  injury; 1 to 6, mild injury. 
62  
We used Doublecortin antibody to label the newly dividing neurons, isolated the 
specific area of neurogenesis in the anterior subventricular zone of the lateral ventricles 
and compared the area of neurogenesis of each treatment in um2. Our results had two 
significant findings and both were with fluoxetine. Fluoxetine vs Control showed a 10- 
fold increase in neurogenesis, while the fluoxetine combination treatment exhibited a 19- 
fold increase in the mean area of neurogenesis for combined hemispheres. 
One neuroscience study showed no change in Brd-U labeling after fluoxetine 
treatment for one week, however when maternally separated rats were treated with 
fluoxetine for a week, the amount of apoptotic cells decreased [92]. These studies 
focused on the dentate gyrus (DG), also known for continued neurogenesis into 
adulthood, but located considerably more caudal than the area we were examining. 
Research has still not been able to determine which cells (stem or progenitor cells) in the 
DG are targeted by the fluoxetine treatments [93]. Additionally, both studies utilized 
injections for treatment administration. 
Injections could have an effect on drug study results due to the interaction of the 
drug and glucocorticoids. Glucocorticoids (stress hormones) play a huge role in 
neurogenesis. Removal of the adrenal gland in rats, leads to an increase in proliferation of 
stem cells or progenitor cells, but when glucocorticoids are high, the formation and 
survival of progenitor cells is decreased [94]. A study using blood samples indicated that 
diurnal rhythms have an impact on corticosterone (stress hormone) levels of both male 
and female rats [95]. The diurnal rhythm guides the rhythm of the progenitor cells [96]. 
Additionally, corticosterone performs a gate-like function with fluoxetine, so that if the 
diurnal rhythm is altered, proliferation as a result of fluoxetine will be altered, as well 
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[96]. When the diurnal rhythm is flattened, as seen in depressed patients, fluoxetine 
seems to have less influence on cell proliferation [96]. The study showed strain 
differences when comparing Lister Hooded (LH) and Sprague Dawley (SD) rats: the LH 
rats, which have a naturally more flattened diurnal rhythm, had a lower progenitor cell 
count. Having a stress free method of administering our treatment helped protect against 
any impact that stress hormone could have had on our experiment. We know that time of 
administration does not affect the results of fluoxetine [97], as fluoxetine has the same 
effect whether it is taken at night or in the morning. It has also been shown that although 
rats are nocturnal, administering the medication during the day would most likely not 
cause any issues. At times, rats modify their activity pattern for survival [98], and this 
includes eating during the day. Additionally, there was no obligation for the rats to eat 
their medication during the day. We left the cookie dough balls in the cages overnight so 
they could eat it whenever they wanted and while most rats woke up to eat the dough 
right away, the occasional rodent would eat it later. For other drugs, timing of medication 
doses may influence results, but because the effects of fluoxetine are cumulative, timing 
did not matter for our study. 
We believe that low stress levels kept glucocorticoids from interfering with the 
experimental treatments. The differences between means and medians increased in the 
following order: Control, Statin, Fluoxetine, Fluoxetine combination. This is as expected 
from the visual observations of neurogenesis, as well as the histogram seen in Figures 3 
and 4, respectively. 
Our results suggest that fluoxetine and fluoxetine combined with simvastatin play 
large roles in neurogenesis and could possibly be influencing various pathways. For 
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instance, since glucocorticoid levels do not seem to be a factor in our study, there does 
not seem to be any long-lasting effects of stress on our test animals and therefore the 
natural effects of fluoxetine may have manifested through increased neurogenesis. 
The glucocorticoid receptor is the main mediator of stress response in 
neurogenesis and neuronal progenitor cells in mammals. It also plays a role in migration 
and functional integration of newborn born neurons [99]. When a mammal is stressed, it 
must exhibit physiological and behavioral changes in order to recover to homeostasis. It 
does not matter in what form the stress presents itself, as the physiological response 
remains predictable [100]. The entire response is orchestrated by the Hypothalamus- 
Pituitary-Adrenal (HPA) axis, which acts in coordination with circadian rhythm [99]. 
In a normal situation, a stressor will act on a mammal causing the hypothalamus 
to release corticotrophin-releasing hormone (CRH), which activate the neuro-endocrine 
cells of the pituitary that express the CRH receptor [101]. The pituitary will release 
adrenocorticotropic hormone (ACTH) into the circulatory system, which stimulates the 
release of stress hormone, adrenal glucocorticoid hormone, from adrenals. In man, these 
adrenal steroid hormones are called cortisol and in rodents, they are referred to as 
corticosterone. Adrenal steroid hormones will feedback to the hypothalamus helping to 
bring the HPA axis back to homeostasis and preventing excess adrenal steroid hormones 
from damaging the body [99]. 
The HPA axis influences a variety of functions, including glucose release, 
immune response, neuroprocessing, such as cognition, long-term potentiation and 
emotional response, as well as cardiovascular functions. With such a high impact role, 
HPA axis stability is an organism’s most important coping mechanism when 
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encountering acute stress. The HPA axis is designed to keep us healthy and adaptable to 
novel situations throughout our lifespan [99] in response to “acute” stress. When the HPA 
axis is never relieved of duty, responding to chronic stress, the system becomes 
unregulated and the normal feedback inhibition fails, which translates into harmful 
effects on multiple systems [102]. 
Adrenal steroid hormone is so powerful across multiple systems because it affects 
the neuron in several ways. Adrenal stress hormones bind both mineralocorticoid (MR) 
and glucocorticoid (GR) receptors found in the cytosol, affecting gene expression when 
the receptors ultimately bind to specific parts of DNA, as well as certain transcription 
factors and co-factors. Additionally, adrenal steroid hormones bind MR and GR found in 
the membrane (59) contributing to neuronal responses that are unrelated to gene changes 
[99]. 
It stands to reason that the more access the brain has to adrenal steroid hormone, 
the more influence this hormone will have on the brain. The hypothalamus has many MR 
and GR receptors, while the close proximity of the dentate gyrus to blood vessels [103] 
may allow for the increased impact of stress through circulation, as stress hormones are 
lipophilic and can pass through the blood brain barrier. This environment could make it 
easy for NPC to be affected by high levels of stress hormone. 
While MR and GR concentrations play a large role in mediating the stress 
response, GR levels have shown to be higher in neuronal precursor cells both in vivo 
[104] and in culture [105]. This leads researchers to believe the GR is the main mediator 
of stress response in neurogenesis and neuronal progenitor cells, while also affecting 
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migration and functional integration of newborn neurons [99]. The role of stress on the 
process of neurogenesis led us to focus on eliminating this variable as much as possible. 
One factor that was in our favor was that the next part of our study included drug 
treatments containing simvastatin. This drug seems to have positive effects on our 
systems irrespective of stress. For instance, simvastatin, as an HMG-CoA inhibitor, 
lowers lipids and may blunt adrenal hormone production [106]. It has been suggested that 
an unborn child can be shielded from the negative effects of maternal stress by treating 
the mother with statins [107]. 
However, our other drug, fluoxetine, is influenced by stress and this will affect 
studies that analyze for its impact on neurogenesis. In 2005, Windle and Corbett studied 
the recovery of motor abilities after focal ischemia, as a function of neurogenesis, using 
fluoxetine in mini pumps [108]. Their rats were half the size of ours, indicating that they 
were also much younger. The rodents endured a stroke surgery in addition to a surgery 
for placement of the mini pump between the shoulder blades. After 21 days, the mini 
pumps had to be changed. Windle and Corbett did not see any neurogenesis in the 
subventricular zone (SVZ) [108]. The stress of multiple surgeries precluded them from 
seeing the influence of fluoxetine. 
Again, stress was shown to negatively influence neurogenesis in the SVZ when 
adult rats were treated with fluoxetine via daily intraperitoneal injections over a two- 
week period of time. This group only examined neurogenesis in the posterior SVZ, as 
they were primarily studying the hippocampus neurogenesis. While neurogenesis in the 
SVZ varies, becoming less as you move further posterior, they should have seen at least a 
small effect of the fluoxetine in the posterior SVZ (as we did), but they did not [109]. 
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This is likely because the stress of the manner of delivery fought against the effects of 
fluoxetine. 
The effect of a stressful drug administration method was tested when glucose 
levels in rats were compared. Diogo et al. tested glucose levels of rats that voluntarily 
ingested their medication and rats that were subjected to oral gavage [110]. Oral 
administration was shown to be highly effective and less stressful on the animal, as well 
[110]. We believe that by having the animals ingest their medications orally, the effects 
of our drugs were not inhibited by the stress of typical administration methods. 
Since we used Doublecortin labeling as our method of identifying migrating 
neurons, we can be sure that these new cells are in migration mode, but we cannot 
confirm that their fate is that of a neuron. Our results showed that these cells were located 
in the subventricular zone, they had divided from either a stem or progenitor cell and they 
were in migration process. They had a 19-fold increase in the mean area of staining when 
treated with the fluoxetine/statin drug combination versus control. A study combining 
this drug combination with more than one marker in the staining process, would allow for 
a higher level of cell fate confirmation and provide more robust results for neurogenesis 
in the animal model. 
In 2006, researchers in China did just that. While neurogenesis in the rodent brain 
has been studied for years, research on human neurogenesis is rarer. A group of scientists 
in China took biopsies in the peri-infarct region of people suspected of having a stroke. 
Their results provided data attesting to similar neurogenesis results in humans, as seen in 
rodents. The experiment used Doublecortin for staining, which confirms that 
Doublecortin will stain migratory cells in the injured region in humans, as it does in 
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rodents. They took the necessary steps to ensure that the data collected were robust. The 
team labeled for multiple markers including endogenous-cell-proliferation markers and 
neuronal-lineage markers. They confirmed migratory neuroblasts co-located next to 
blood vessels. Carmichael’s lab has shown similar results for this co-location of 
migratory neuroblasts and blood vessels, as well [111]. Together these data provided 
evidence that humans also undergo neurogenesis after stroke [112]. 
Controllable vs Uncontrollable Stress 
 
There seems to be a physiological difference between controllable and 
uncontrollable effects of stress. Here we have focused on the negative impacts of stress 
on neurogenesis in the brain. The HPA axis activation promotes neurogenesis showing 
that increased stress and adrenal hormones affect the body differently when that stress 
can be controlled [99]. Exercise increases stress hormones in the blood [113]. 
Interestingly, this type of controlled stress will also support neurogenesis at the 
proliferation stage and foster differentiation [99], while also facilitating survival of the 
newborn neurons within the dentate gyrus of the rat [114]. There is a possibility that the 
positive effect on neurogenesis seen with exercise is linked to the increase in eNOS 
activity that are seen with increased physical activity as well as social interaction [114]. 
Learning, enriched environment and sexual experience have shown similar results, 
promoting proliferation and integration of new neurons [99] [115]. 
Researchers identified a difference between acute and chronic sexual experience. 
 
While both increased circulating stress hormone, acute sexual experience increased 
proliferation in the dentate gyrus and chronic experience increased both neurogenesis and 
proliferation in the dentate gyrus of the adult rat [116]. The opposite is true for 
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uncontrollable stress such as social defeat, fear and chronic stress (vs acute). In this case, 
stem/progenitor cell proliferation and integration are both inhibited in response to 
increased stress [99]. The fact that uncontrollable stress has a negative impact on 
neurogenesis seems to hold true independent of species, age or stressor. Similar reports 
are documented with the mouse, rat, tree shrew and marmoset [117]. Studies examining 
many uncontrollable stressors, such as resident-intruder, predator odor, isolation and cold 
swim, all observed an inhibition of cell proliferation [117]. 
Although it is clear that the nature of the stressor plays the most important role, 
the complexity of the stress system has made it difficult to identify the underlying 
mechanisms that differentiate each physiological response [99]. 
The neurogenesis we observed could be the effect that these drugs, as well as 
stress have on growth factors, Brain-Derived Neurotropic Factor (BDNF) and Vascular 
Endothelial Growth Factor (VEGF). BDNF is a neurotrophin that plays an important role 
in the survival and differentiation of new neurons in the nervous system [118]. This was 
verified when SVZ neuroblasts displayed long-term survival after being given BDNF 
[119]. Viral overexpression of BDNF in the lateral ventricles nearly doubles the 
production of new neurons in the olfactory bulb [120]. BDNF not only helps maintain 
neuronal physiological activity [121], but it also enhances synaptic plasticity, enabling 
long-term potentiation [122]. BDNF expression is increased with hypoxia and is required 
for the proper development and survival BDNF of serotonergic, GABAergic, cholinergic 
and dopaminergic neuron development [123] [124]. 
VEGF is also upregulated in response to hypoxia and stimulates angiogenesis. 
VEGF is an angiogenic, and can stimulate neurogenesis both in vitro and in vivo [125]. 
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In endothelial cells, VEGF can protect and promote cell survival [126], [127]. Neurons 
express VEGF receptors similar to endothelium allowing some of the same functions to 
be performed across both cell types [125]. 
Fluoxetine increases the gene expression for BDNF [128] as well as the 
expression of VEGF [129], so we hypothesized that without undue stress antagonizing 
these effects, these growth factors could induce neurogenesis in our rat model. Both 
BDNF and VEGF have been shown to increase in expression in response to simvastatin 
in the dentate gyrus, although more caudal than the anterior SVZ, where we were 
investigating [130]. It makes sense that treatment with fluoxetine would increase 
neurogenesis in our model and that combined with simvastatin, we might see more 
enhanced results. We are the first study to show increased neurogenesis in the SVZ in 
response to fluoxetine in rats. 
Gene Analysis 
 
Within the fluoxetine treatment versus vehicle, the up-regulated genes were 
largely involved in channel activity (10 genes, p<0.05). Fluoxetine modifies the 
conductance of the voltage-dependent anion channel (VDAC) which is also called a 
mitochondrial porin [131]. The modification of conductance ultimately prevents the 
release of cytochrome c and protects against apoptosis [131]. Other voltage dependent 
channels that fluoxetine has been found to affect include Na+/K+ and Ca+ channels [132] 
and [133]. Our gene analysis showed that there changes in channel activity when treated 
with fluoxetine versus control. 
When we looked at the up-regulated genes associated with the fluoxetine 
combination treatment, the effect of statins on clotting activity was very apparent. Statins 
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may reduce the effect of stroke by up-regulating eNOS [134]. Endothelial nitric oxide 
synthase (eNOS) is an enzyme that serves as a protectant in vascular smooth muscle 
[135]. ENOS is anti-thrombotic, anti-inflammatory and reduces smooth muscle 
hypertrophy in blood vessels. A lack of eNOS leads to platelet aggregation, increased 
smooth muscle proliferation, greater leukocyte adhesion to the endothelium and a rise in 
blood pressure [135]. 
The up-regulation of eNOS not only inhibits clotting activity, but also leads to an 
increase in circulating endothelial progenitor cells (EPC) [135]. Together eNOS and 
EPCs promote vascular health by boosting angiogenesis, reducing atherosclerosis and 
supporting vascular repair [70]. This corresponds to the reduction in the immune 
response we saw during our gene analysis when comparing the statin treatment group 
against the control group. 
Interestingly, we also found a significant effect in the fluoxetine combination 
treatment group versus the statin treatment group involving a set of down-regulated genes 
associated with the immune response. This could be due to statins down-regulating effect 
on the pro-inflammatory chemokine network [136] or the influence of fluoxetine 
treatment on the M1 inflammatory type microglia and M2 growth supportive microglia 
subtype [137]. 
The M1 type microglia are necessary during an immune response, as they will 
remove debris from the wound, kill tumors and initiate the recruitment of the M2 
microglia to assist in new blood vessel growth and the deposition of extracellular matrix. 
In order to do their jobs, the M1 microglia must release pro-inflammatory cytokines. 
However, during wound sterilization, the surrounding healthy tissue may also be 
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damaged [138]. However, with the statin treatment creating anti-inflammatory effects, 
the pro-inflammatory cytokine response could be markedly decreased. 
Fluoxetine treatment downregulates the expression of the M1 inflammatory type 
microglia and upregulates the expression of the M2 supportive microglia subtype [137]. 
Our gene analysis found a trend towards reduced immune response in our Fluoxetine 
combination treatment group and this could be due to the roles that chemokines play 
during the microglia activation stages. For instance, while some chemokines are 
produced in high concentrations to guide the migration of inflammatory cells to an injury 
site, others are involved in anti-inflammatory roles. The down regulating of IL-8 
expression, if present in leukocytes, will inhibit inflammation and thrombotic effects, 
while activation of macrophages in the presence of IL-4 or IL-13 will promote 
angiogenesis and matrix remodeling and suppress destructive immune response through 
support of the M2 macrophage [139]. Statins have the ability to promote a Th2 type of 
response as one of their many immunomodulatory properties [140]. The Th2 response 
consists of increased expression of IL-4, IL-5 and IL-13. The switch from the M1 
inflammatory response to the M2 response involving the production of neuroprotective 
factors involved in the repair, is induced by the stimulation of anti-inflammatory 
cytokines IL-4 and IL-13. 
To refine these findings, future experiments could focus on the influence of 
fluoxetine and simvastatin on these different chemokines. Additionally, the real time 
PCR gene analysis should be performed to assess if the results found in our rat Gene Chip 
analysis are reproducible, particularly in regards to the effects of fluoxetine and statins 
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ability to change a phenotype of an inflammatory M1 microglia into an M2 growth 
supportive microglia. 
The Gene Ontology Analysis 
 
Our gene analysis showed the most significant effects in the two fluoxetine 
treatment groups, with both of them upregulating gene sets for Forkhead box alpha-1 
(Foxa1) and Hypoxia-inducible factor 1-alpha (HIF1a). FoxA1, which is sometimes 
referred to as Hepatocyte nuclear factor-3 alpha (HNF-3a) was first identified in the liver 
and is characterized by the forkhead binding domain, which is a highly conserved protein 
domain specifically shaped for DNA-binding. It is essential for endodermal development 
[141]. Additionally dose dependent roles of FoxA1/A2 have been identified during 
development to regulate differentiation of dopaminergic neurons in the midbrain [142]. 
With strong ties to embryogenesis and a consistent role in differentiation, the Fox 
gene family was an expected find during our study and analysis. Using fluoxetine in our 
experiments could have enhanced the probability of this expression, since fluoxetine 
seems to increase neurogenesis and the Fox family is tied to this process. Another 
influencing factor in this study could be our inclusion of ascorbic acid, which has been 
shown to increase the number of dopaminergic neurons [143], while the Fox family plays 
a role in dopaminergic neuron differentiation [142]. This study did not look into every 
link, but since fluoxetine has also been shown to increase dopamine in the extracellular 
space, the administration of this SSRI could have influenced the gene analysis by 
influencing other processes, as well. 
Hypoxia-inducible factor 1-alpha (HIF-1-a) is a gene involved in the response to 
hypoxia. Fluoxetine has been shown to increase expression of HIF1A protein above that 
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of control in stroke model mouse [144]. Angiogenesis and hypoxia have been linked in 
studies of ischemic environments [145]. Hypoxia stimulates vascular progenitors that 
express endothelial markers like eNOS and growth factors such as vascular endothelial 
growth factor, VEGF [145]. 
As HIF begins to accumulate, the transcription of growth factors, BDNF and 
VEGF increases and the up-regulation of vascular progenitors will occur near the 
ischemic site. VEGF promotes angiogenesis through phosphorylation of Akt, which 
activates the pathway that increases eNOS levels [145]. Although we did not target 
angiogenesis as the focus of the experiment, vascularization is necessary for neurogenesis 
to be significant and survive long-term. Thus, our results suggest vascularization took 
place at some level. Future studies testing our drug combination with an assay for 
endothelial cell migration for VEGF would be beneficial to confirm this suggestion. We 
know that both simvastatin and fluoxetine increase BDNF and VEGF: it is possible that 
targeted increases in HIF1A that produce these changes. We did not see any evidence of 
infarcts in these animal models, either functionally or in the dissected brain, so the 
HIF1A would not have been produced by ischemia per se in our experiments. More 
research is necessary to understand the direct effect of these drugs on Hypoxia Inducible 
Factor 1A. 
When we examined the results of the simvastatin/ascorbic acid treatment group 
versus vehicle we found that the differentially expressed genes up-regulated with a >2 
fold change (p<0.05) belonged to mostly to the ontology of biological processes. Most 
importantly, the biological processes are involved in transport, regulation and response, 
Table 22. Within this same comparison, the simvastatin/ascorbic acid treatment group 
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versus vehicle, we identified the differentially expressed genes, Alpha-2-macroglobin 
(A2m), Protein kinase c-delta (Prkcd), Sclerostin domain containing-1 (Sostdc1), which 
are common to a variety of signaling pathways, Table 23. 
The gene named Alpha 2 Macroglobulin (A2M) showed in our genetic ontology 
report as a significant contributor to our results. It encodes for a protein that binds brain- 
derived neurotropic factor (BDNF) and is considered an acute-phase protein available 
when the body encounters challenges such as cardiac infarctions [146]. Scientists have 
found a role for A2M in the coagulation cascade pathway in rats [147]. Although our 
method of inducing coagulation of the MCA was not successful, the action itself could 
have had implications that influenced this gene activation and its presence in our gene 
analysis. 
Protein kinase c-delta (Prkcd) belongs to a family activated by calcium and 
diacylglycerol. The family can phosphorylate multiple protein targets making it 
responsible for a wide array of cellular signaling pathways. This particular gene plays a 
role in growth and apoptosis regulation, in addition to differentiation of an assortment of 
cell types [148]. Protein kinase c has been shown to be a mediator of reperfusion injury in 
different organs [149]. A peptide inhibitor selective for PKC reduced cellular injury in rat 
hippocampus slices. The same researchers used an in vivo rat stroke model, occluding the 
MCA, where the infarct size was decreased when the peptide inhibitor was used. There 
was no effect when this inhibitor was delivered before injury. Decreased infarct size was 
only seen when the PKC inhibitor was delivered at onset, 1 hour and 6 hours of 
reperfusion [148]. The same researchers went on to find that PKC also decreased 
apoptosis and increased the levels of phosphorylated Akt [148]. As previously 
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mentioned, the hypoxic response increases phosphorylated Akt, which in turn increases 
eNOS and is involved in cell survival pathways. Future research could be done to discern 
the specific roles of the PKC gene and investigate techniques to regulate the expression. 
These results could possibly provide leverage for the advancement in the genetic 
treatment of stroke [148]. 
The Sclerostin domain containing-1 gene, encodes for the protein also known as 
Wise. Wise indirectly affects proliferation, differentiation and apoptosis by associating 
with bone morphogenetic protein (BMP). Through association, Wise prevents BMP from 
binding to receptors [150]. Wise is a Wnt modulator and will reduce BMP signaling in 
fibroblasts. Scientists believe that Wnt pathway is active and acts on the hippocampus 
throughout the lifespan [151]. Long-term potentiation is the result of Wnt ligand acting 
locally to shape the pre and post synaptic connections [150]. 
While our gene results were interesting and provided a good baseline for future 
studies, we cannot be sure that we would get the same results if we had analyzed tissue 
from the subventricular zone. The lab has continued studies with in gene expression in 
the peri-infarct area after endothelin-induced stroke and has shown through real time 
PCR that our drugs decrease the inflammatory response of the immune system and 
increase growth factors, leading to a smaller infarct size [152] (work involving 
Dissertation research by Moner Ragas, and thesis work of Dr. Neal Verma.) 
Biology and Statistics 
 
Statistics play a large role in scientific research. Interpreting causality and 
probability under specific conditions, paves our way to understanding how we can 
improve the lives of humans, animals and the planet. Biology is a unique discipline. 
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Understanding biology means grasping the concepts of mechanisms, how they overlap to 
influence one another and the influence of behavior, environment and chemicals on these 
mechanisms. Biology is not always predictable and the randomness of the science is the 
beauty. What we do know is that we can influence biology, as stated before, through 
behavior, environment and chemicals. That is what we are trying to do when we set up 
biological experiments. However, when we use statistics to describe our results, it should 
be with the knowledge that biology is not a static system. At the macroscopic level, 
biology can be described with methodical language, laws of physics and hard statistics. 
But, the smaller we go, the more molecular we get, and embedded we become in the 
mechanisms of a living system that will never behave the same as a nonliving object. 
This research shows great significance in the mean area of Doublecortin staining 
while using our drug combination treatment. We took measures to remove stress from the 
administration method to keep that variable out of our results. In one statistical 
measurement we saw that when we analyzed the area using a smaller unit, micrometers 
squared, we gained significance within the fluoxetine treatment group that was not there 
when we analyzed in millimeters squared. When we changed from millimeters squared to 
micrometers squared, we increased the numerical range, which made it easier to identify 
a statistical significance. When performing statistics on a living animal, there will be a lot 
of variability from animal to animal. The genetic variability will influence how the drugs 
work on them, but the ultimate test is to have this research on a living animal before 
moving on to clinical trials. When we examined Doublecortin staining in millimeters 
squared, we saw a 19-fold increase in the mean area of Doublecortin staining with the 
fluoxetine combination group, which was significant and an 11-fold increase in the 
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fluoxetine treatment group, which was not significant. Although, not statistically 
significant in millimeters squared, an 11-fold increase in neurogenesis would likely have 
biologically significant effects on a living creature. We saw this difference in significance 
simply because the sensitivity of our statistical tests increased with the greater numerical 
range. 
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Conclusion 
 
One of the largest issues in conducting experiments with live animals is the risk of 
stress interfering with the results. The first part of this study brought great results as we 
identified a medium for the voluntary oral administration of medication using plain sugar 
cookie dough. The method was tested in two different strains of rats (Fisher and Wistar), 
in addition to both genders in the Fisher strain and found to be reliable 99.48-100% of the 
time. We now have a method of medication administration that eliminates the 
unnecessary stress and extreme weight loss that can be seen when using IP injections or 
oral gavage. 
We looked at three different drug treatments and their effect on neurogenesis. 
 
Fluoxetine (5mg/kg), simvastatin (0.5 mg/kg) plus ascorbic acid (20 mg/kg) and a 
combination treatment of fluoxetine, simvastatin and ascorbic acid (5mg/kg, 0.5mg/kg, 
20mg/kg, respectively) were tested against control (no treatment). We found that the 
combination of fluoxetine and statin with ascorbic acid produced the most effective and 
significant results. The efficacy is demonstrated through increased area of Doublecortin 
staining in the anterior lateral ventricles of the SVZ. The staining identified neurons 
expressing the Doublecortin protein, which is found in neuroblasts and when compared 
with control, the fluoxetine combination treatment showed a 19-fold increase in mean 
area of neurogenesis. 
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Neurologists can utilize these results as a step towards increasing neurogenesis for 
improvement in multiple disorders, such as Alzheimer’s, stroke, Parkinson’s, 
depression,addiction and PTSD. Additionally, by drawing the parallel between the 
dynamic instability of microtubules and their role in neurogenesis, computer scientists 
can study the mechanisms and hypothesize concepts for autonomous systems that react to 
external stimuli by reconfiguring the circuit [153]. 
Since not all mechanisms of neurogenesis are understood and we do not hold a 
firm understanding of how to manipulate or control neurogenesis, it is necessary that we 
track and study the genetic component that is integrated within the process. To add 
another layer of information to the study, we had a gene chip analysis performed on 
cortical tissue that received the different drug treatments. We think it is critical to the 
future management of neurogenesis to understand which genes are involved and to what 
extent. If we identify which genes are regulating neurogenesis we can look into possible 
modes of manipulation. The gene study that we performed added useful information but 
we were not able to confirm the results we were seeing at that time with real time PCR. 
For the study to supply pertinent results for future applications, we would have needed to 
use samples near the subventricular zone. Additionally, we will need to be meticulous in 
our processes and not to assume direct correlations between gene expression and protein 
expression. Many things can affect gene expression. At times, an upregulation of gene 
expression does not cause a protein to be expressed. It is not uncommon to have false 
positives in gene chips with the dynamics in such a nonlinear system. In order to get a 
broader idea of what was going on, we used the less rigorous method of gene expression: 
gene chip. We would need to go back and retest these results with real time PCR if we 
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wanted to validate these findings. Once we have labeled and performed a gene chip study 
using the specific area, the next steps are to confirm protein expression with IHC and 
Western blot and confirm gene chip expression with real-time PCR. We did not get to 
confirm our gene chip with PCR methods so there could have been false positives in 
these early results. We cannot rely on the gene chip analysis alone. 
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Future Studies 
 
Noting that there is a physiological difference between controlled and 
uncontrolled stress, these conditions should be compared utilizing the fluoxetine 
combination treatment. Given that controlled stress has the ability to facilitate survival of 
newborn neurons, our results with the drug combination could possibly be enhanced or 
even strengthened. Since learning, enriched environment and sexual experience have also 
been shown to increase neurogenesis, any of these avenues should be explored in 
conjunction with the drug treatment, as well. 
We did not see an increase in BDNF or VEGF in our gene results. These growth 
factors are highly localized around the infarct region and the Doublecortin expression 
region because Doublecortin is attracted to BDNF. By using cortex rather than SVZ 
samples for the gene expression studies, we decreased the possibility that we would see 
these growth factors, particularly since we did not induce an infarct with our stroke 
surgery. Later studies from this laboratory have focused on the peri-infarct region for the 
gene expression analysis, and have shown increase in a number of growth factors, 
including BDNF. If we can use our drug combination to increase neurogenesis and both 
of these growth factors that facilitate the process, we can begin to look at novel 
approaches to treatment of stroke, as well as gene therapy. 
Next time, we should not look solely at cells that label with Doublecortin, but also 
look at cells that label with neuronal nuclear protein (NeuN). NeuN, although exclusively 
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found in nervous tissue, it is not found in immature neural progenitor cells, nor is it 
detected in glial cells [154]. This suggests that it is specific for marking the neuronal 
phenotype. A benefit is that NeuN expression is associated with the nucleus instead of the 
cytoplasm, which allows the cells to be more discretely stained and therefore makes it 
easier for later binary image processing [154]. 
NeuN is a product of Fox-3, which is also expressed only in nervous tissue and 
has the exact same Immunocytochemistry staining pattern as NeuN [154]. Fox-3 belongs 
to the Fox-1 family [154] and we saw a change in the Fox gene in our genetic analysis. 
Performing a neurogenesis study to test our drug combination using Western blot in 
combination with IHC could provide the powerful results we need to revisit our gene 
analysis on Fox1. 
Lastly, it has been found that physical activity increases the proliferation of 
microglia and that ageing is associated with increased microglia activation towards the 
M1 inflammatory phenotype. Studies performed using physical activity and the 
fluoxetine/statin drug combination could prove to support the M2 response, as a way to 
clear debris and necrotic tissues while promoting neurogenesis [139]. This same approach 
could be used as a treatment program with ageing individuals as a preventative measure. 
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Appendix 
Up‐regulated and Down‐regulated Genes 
 fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb 
IGG2A_RAT 3.640024935 ‐1.100687302 ‐1.217169426 ‐4.43052706 
Ttr 3.347527715 ‐1.248152315 5.104085513 1.524732862 
Kcnj13 3.133986938 1.140047683 2.105326761 ‐1.488598823 
LOC100363671 3.09393953 1.123327812 ‐1.038105691 ‐3.211836232 
Sostdc1 2.865361175 ‐1.037633527 2.379233171 ‐1.204321295 
Clic6 2.647506574 ‐1.042854679 1.931338442 ‐1.370814414 
Cldn2 2.581984488 ‐1.03055226 1.640486059 ‐1.573914313 
Cxcl13 2.421881594 ‐1.158783194 1.137900964 ‐2.128376432 
Prkcd 2.323790449 1.613633765 1.522909043 ‐1.525889193 
Cacna1i 2.250675918 2.48733415 2.721100045 1.2090146 
     
     
 fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb 
LOC100361322 ‐2.944293175 ‐2.419071369 ‐3.143416266 ‐1.067630185 
F1M6L0_RAT ‐2.372844677 ‐1.517038466 ‐1.955033506 1.213710491 
RGD1560095 ‐2.355208854 ‐1.536143508 ‐2.146619765 1.097170953 
D3ZUT2_RAT ‐2.322559141 ‐1.631958458 ‐1.713926212 1.355110345 
D3ZZI9_RAT ‐2.289411293 ‐1.33040608 ‐1.816983099 1.260006928 
Gucy2f ‐2.286089681 ‐1.21093716 1.082469718 2.474622853 
RGD1565410 ‐2.229691326 ‐1.356263972 ‐2.244537708 ‐1.006658492 
F1M1X1_RAT ‐2.223150062 ‐1.687300968 ‐1.054306984 2.10863638 
F1M4J8_RAT ‐2.162771624 ‐1.754740062 ‐1.845331489 1.172023367 
F1M9E2_RAT ‐2.162609975 ‐1.58926918 ‐2.073836992 1.042806153 
     
     
 fold‐Fluoxetine_vs_Vehicle fold‐Simv+Ascorb_vs_Vehicle fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb 
Lrrc7 2.619065245 1.967819644 2.228693668 1.132570088 
Cacna1i 2.48733415 2.250675918 2.721100045 1.2090146 
D3ZCX4_RAT 2.294937716 1.31545783 1.593197366 1.211135264 
U2 2.244341686 1.498790079 2.059896237 1.374372746 
U2 2.244341686 1.498790079 2.059896237 1.374372746 
F1M4F6_RAT 2.189673348 1.517145726 1.943681277 1.281143429 
U6 2.162407369 1.527408898 2.271788193 1.487347753 
rno‐mir‐384 2.161533706 1.439282045 1.792456781 1.245382576 
Slc12a6 2.111941686 2.216010934 1.681517935 ‐1.317863395 
rno‐mir‐380 2.05746706 1.47775114 1.709222247 1.156637407 
     
     
 fold‐Fluoxetine_vs_Vehicle fold‐Simv+Ascorb_vs_Vehicle fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb 
F1M4A3_RAT ‐3.115556759 ‐1.474291699 ‐1.159493715 1.271496067 
LOC100361322 ‐2.419071369 ‐2.944293175 ‐3.143416266 ‐1.067630185 
LOC100360329 ‐2.180870845 ‐1.139174165 ‐2.302729582 ‐2.021402567 
Fam71e2 ‐2.088526332 ‐1.380490857 ‐1.29713173 1.064264195 
D4A684_RAT ‐2.07231742 ‐1.595934011 ‐1.408103454 1.133392583 
F1M509_RAT ‐2.033976015 ‐1.82305826 ‐2.455190553 ‐1.346742782 
F1LYV9_RAT ‐1.994479553 ‐1.807059905 ‐1.798947811 1.004509355 
D4ABQ4_RAT ‐1.969484869 ‐1.217934319 ‐1.121470496 1.086015479 
LOC100364560 ‐1.953579545 ‐1.114117968 ‐1.933002272 ‐1.735006819 
Mup4 ‐1.948709897 ‐2.044725721 ‐2.31145162 ‐1.130445808 
     
     
 fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle 
Ttr 5.104085513 1.524732862 3.347527715 ‐1.248152315 
Cacna1i 2.721100045 1.2090146 2.250675918 2.48733415 
Sostdc1 2.379233171 ‐1.204321295 2.865361175 ‐1.037633527 
U6 2.271788193 1.487347753 1.527408898 2.162407369 
Lrrc7 2.228693668 1.132570088 1.967819644 2.619065245 
Kcnj13 2.105326761 ‐1.488598823 3.133986938 1.140047683 
U2 2.059896237 1.374372746 1.498790079 2.244341686 
U2 2.059896237 1.374372746 1.498790079 2.244341686 
D3ZX37_RAT 2.049844777 1.005603702 2.038422066 1.585700822 
Mug1 2.03181634 1.51658252 1.339733455 1.430760307 
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 fold‐Sim+Asc+Flu_vs_Vehicle fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle 
LOC100361322 ‐3.143416266 ‐1.067630185 ‐2.944293175 ‐2.419071369 
D3ZPQ1_RAT ‐2.654006063 ‐1.359310147 ‐1.952465424 ‐1.411529226 
LOC100364370 ‐2.539782581 ‐1.324562574 ‐1.917450056 ‐1.774808048 
F1M509_RAT ‐2.455190553 ‐1.346742782 ‐1.82305826 ‐2.033976015 
Ly49i3 ‐2.354999358 ‐1.36566882 ‐1.724429323 ‐1.36119806 
Dpt ‐2.313763915 ‐1.133615194 ‐2.041048786 ‐1.764883148 
Mup4 ‐2.31145162 ‐1.130445808 ‐2.044725721 ‐1.948709897 
LOC100360329 ‐2.302729582 ‐2.021402567 ‐1.139174165 ‐2.180870845 
RGD1564848 ‐2.265019284 ‐1.208845424 ‐1.873704644 ‐1.6165882 
RGD1565410 ‐2.244537708 ‐1.006658492 ‐2.229691326 ‐1.356263972 
     
     
 fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle fold‐Sim+Asc+Flu_vs_Vehicle 
Gucy2f 2.474622853 ‐2.286089681 ‐1.21093716 1.082469718 
F1M1X1_RAT 2.10863638 ‐2.223150062 ‐1.687300968 ‐1.054306984 
Abhd15 2.043063436 ‐1.720089937 ‐1.412971141 1.187765472 
Myo7b 1.922828377 ‐1.24287396 ‐1.024242977 1.547082358 
rno‐mir‐142 1.897696132 ‐1.262232201 1.186115636 1.503444558 
D3ZQ54_RAT 1.848531549 ‐1.318370927 1.387578764 1.402133126 
LOC683745 1.84192204 ‐1.576999278 ‐1.409899179 1.167991682 
D3ZH73_RAT 1.786042404 ‐1.485454759 1.139587209 1.202353955 
D4A8P2_RAT 1.755856569 1.017082471 1.237416063 1.785850939 
F1LVU9_RAT 1.735562116 ‐1.321855675 ‐1.375963945 1.312973987 
     
     
 fold‐Sim+Asc+Flu_vs_Simv+Ascorb fold‐Simv+Ascorb_vs_Vehicle fold‐Fluoxetine_vs_Vehicle fold‐Sim+Asc+Flu_vs_Vehicle 
IGG2A_RAT ‐4.43052706 3.640024935 ‐1.100687302 ‐1.217169426 
LOC100363671 ‐3.211836232 3.09393953 1.123327812 ‐1.038105691 
RT1‐Da ‐2.396851288 1.952817416 ‐1.166894825 ‐1.227381151 
F1LV34_RAT ‐2.371643231 1.321883773 ‐1.256712523 ‐1.794139 
IGG2B_RAT ‐2.33821431 1.668500555 ‐1.069501743 ‐1.401386594 
F1LPR6_RAT ‐2.158869444 1.727875576 1.066447787 ‐1.249435708 
Cxcl13 ‐2.128376432 2.421881594 ‐1.158783194 1.137900964 
Gpr88 ‐2.108574019 1.362403771 1.020890642 ‐1.54768657 
Cd74 ‐2.074565749 1.969342964 1.081091311 ‐1.053430401 
F1LNR3_RAT ‐2.061841834 1.734630843 ‐1.080300994 ‐1.188634368 
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Down in S+A vs V 
Gene Profiler 
 
 
Up-regulated in Fluoxetine vs Control         
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PRKCD,A2M,CD74,ACE,SERPING1,FC 
ER1G,C4B,LEF1,RSAD2,C1S,RT1-BB 
1 1.24E-03 193 101 9 0.089 0.047 GO:0002443 BP 9 
leukocyte mediated 
immunity 
2 
PRKCD,CD74,ACE,SERPING1,FCER1G, 
C4B,RSAD2,C1S,RT1-BB 
1 1.95E-03 150 101 8 0.079 0.053 GO:0002449 BP 9 
lymphocyte mediated 
immunity 
3 
PRKCD,CD74,SERPING1,FCER1G,C4B, 
RSAD2,C1S,RT1-BB 
 
 
1 
 
 
3.41E-02 
 
 
1147 
 
 
101 
 
 
18 
 
 
0.178 
 
 
0.016 
 
 
GO:0048584 
 
 
BP 
 
 
9 
 
positive regulation of 
response to stimulus 
 
 
1 
CXCL13,PRKCD,A2M,CD74,SHOX2,AC 
E,SERPING1,FCER1G,C4B,KL,F1M784_ 
RAT,NRG1,CD4,EGFR,RSAD2,C1S,RT1- 
BB,DRD2 
 
 
1 
 
 
1.86E-03 
 
 
738 
 
 
101 
 
 
16 
 
 
0.158 
 
 
0.022 
 
 
GO:0006955 
 
 
BP 
 
 
9 
 
 
immune response 
 
 
1 
CXCL13,PRKCD,A2M,CD74,RT1- 
DA,SERPING1,FCER1G,C4B,F1M784_R 
AT,FCGR3A,CD4,LEF1,RSAD2,C1S,CX 
CL16,RT1-BB 
1 6.25E-04 178 101 9 0.089 0.051 GO:0002250 BP 9 
adaptive immune 
response 
2 
PRKCD,CD74,SERPING1,FCER1G,C4B, 
LEF1,RSAD2,C1S,RT1-BB 
 
 
 
1 
 
 
 
3.28E-04 
 
 
 
165 
 
 
 
101 
 
 
 
9 
 
 
 
0.089 
 
 
 
0.055 
 
 
 
GO:0002460 
 
 
 
BP 
 
 
 
9 
adaptive immune 
response based on somatic 
recombination of immune 
receptors built from 
immunoglobulin superfamily 
domains 
 
 
 
3 
 
 
PRKCD,CD74,SERPING1,FCER1G,C4B, 
LEF1,RSAD2,C1S,RT1-BB 
1 6.43E-04 88 101 7 0.069 0.08 GO:0019724 BP 9 
B cell mediated 
immunity 
4 
PRKCD,CD74,SERPING1,FCER1G,C4B, 
C1S,RT1-BB 
 
1 
 
5.94E-04 
 
87 
 
101 
 
7 
 
0.069 
 
0.08 
 
GO:0016064 
 
BP 
 
9 
immunoglobulin 
mediated immune response 
 
5 
PRKCD,CD74,SERPING1,FCER1G,C4B, 
C1S,RT1-BB 
 
1 
 
3.41E-02 
 
447 
 
101 
 
11 
 
0.109 
 
0.025 
 
GO:0002684 
 
BP 
 
9 
positive regulation of 
immune system process 
 
1 
CXCL13,A2M,CD74,SERPING1,FCER1G 
,C4B,F1M784_RAT,CD4,RSAD2,C1S,RT 
1-BB 
1 2.25E-02 275 101 9 0.089 0.033 GO:0050778 BP 9 
positive regulation of 
immune response 
2 
A2M,CD74,SERPING1,FCER1G,C4B,F1 
M784_RAT,RSAD2,C1S,RT1-BB 
1 5.03E-03 43 101 5 0.05 0.116 GO:0072376 BP 15 
protein activation 
cascade 
1 A2M,F5,SERPING1,C4B,C1S 
 
 
 
1 
 
 
 
1.15E-02 
 
 
 
2416 
 
 
 
101 
 
 
 
29 
 
 
 
0.287 
 
 
 
0.012 
 
 
 
GO:0006950 
 
 
 
BP 
 
 
 
10 
 
 
 
response to stress 
 
 
 
1 
CXCL13,PRKCD,PALB2,SLC12A6,A2M, 
CD74,LRRC7,ACE,F5,PAX6,KRT8,PLA 
C8,SERPING1,FCER1G,C4B,KL,OLR1,F 
ZD6,F1M784_RAT,FCGR3A,PENK,CD4, 
EGFR,GFAP,RSAD2,C1S,CXCL16,RT1- 
BB,DRD2 
 
 
1 
 
 
3.84E-05 
 
 
804 
 
 
101 
 
 
19 
 
 
0.188 
 
 
0.024 
 
 
GO:0006952 
 
 
BP 
 
 
10 
 
 
defense response 
 
 
2 
CXCL13,PRKCD,A2M,CD74,ACE,PLAC 
8,SERPING1,FCER1G,C4B,KL,OLR1,F1 
M784_RAT,PENK,CD4,EGFR,RSAD2,C1 
S,CXCL16,RT1-BB 
 
1 
 
2.29E-03 
 
750 
 
101 
 
16 
 
0.158 
 
0.021 
 
GO:0009611 
 
BP 
 
10 
 
response to wounding 
 
2 
PRKCD,A2M,ACE,F5,PAX6,SERPING1, 
FCER1G,C4B,KL,OLR1,FZD6,F1M784_R 
AT,FCGR3A,EGFR,GFAP,DRD2 
 
 
1 
 
 
3.19E-03 
 
 
1401 
 
 
101 
 
 
22 
 
 
0.218 
 
 
0.016 
 
 
GO:0044459 
 
 
CC 
 
 
13 
 
 
plasma membrane part 
 
 
1 
CACNA1I,SLC12A6,CD74,RT1- 
DA,ACE,TRPM6,KRT8,SCN7A,ACVR1 
C,SLC4A5,FCER1G,FOLR1,FZD6,FCGR3 
A,NRG1,MYO1D,GNAL,CD4,ITGAM,EG 
FR,RT1-BB,DRD2 
1 4.99E-02 1 30 1 0.033 1 CORUM:3277 co 12 
D2 receptor-Nsf-GluR2 
complex 
1 DRD2 
1 4.99E-02 1 30 1 0.033 1 CORUM:2277 co 4 
D2 receptor-GluR2- 
GluR1 complex 
1 DRD2 
1 1.44E-03 11 97 4 0.041 0.364 HP:0002725 hp 2 
Systemic lupus 
erythematosus 
1 SERPING1,C4B,ITGAM,C1S 
1 6.97E-03 67 101 5 0.05 0.075 KEGG:04610 ke 3 
Complement and 
coagulation cascades 
1 A2M,F5,SERPING1,C4B,C1S 
1 4.64E-02 152 101 6 0.059 0.039 KEGG:04514 ke 14 
Cell adhesion molecules 
(CAMs) 
1 
CLDN2,RT1- 
DA,CD4,ITGAM,NFASC,RT1-BB 
1 1.19E-04 53 101 6 0.059 0.113 KEGG:05150 ke 8 
Staphylococcus aureus 
infection 
1 
RT1-DA,C4B,FCGR3A,ITGAM,C1S,RT1- 
BB 
 
1 
 
2.33E-02 
 
645 
 
101 
 
12 
 
0.119 
 
0.019 
 
MI:hsa-miR-892a 
 
mi 
 
16 
 
MI:hsa-miR-892a 
 
1 
SLC12A7,A2M,ACE,TMEM72,LY49SI1, 
KL,MYO1D,CD4,LEF1,FCRLS,CYP2J10, 
C1S 
1 4.25E-02 50 101 5 0.05 0.1 REAC:440458 re 5 TCR signaling 1 PRKCD,RT1-DA,UBC,CD4,RT1-BB 
1 1.59E-02 41 101 5 0.05 0.122 REAC:440457 re 5 
Downstream TCR 
signaling 
2 PRKCD,RT1-DA,UBC,CD4,RT1-BB 
1 7.23E-03 17 101 4 0.04 0.235 REAC:428237 re 5 
Change of PKC theta 
conformation 
3 PRKCD,RT1-DA,CD4,RT1-BB 
88 
 
 
 
 
 
 
Up in S+A+F vs V 
        
 
# 
 
p-value 
 
T 
 
Q 
 
Q&T 
 
Q&T/Q 
 
Q&T/T 
 
term ID 
 
t type 
 
t group 
t name and depth in 
group 
  
Q&T list 
#             
 
1 
 
1.53E-02 
 
2 
 
51 
 
2 
 
0.039 
 
1 
 
GO:0060838 
 
BP 
 
3 
lymphatic endothelial cell 
fate commitment 
 
1 
 
NR2F2,PROX1 
 
 
 
1 
 
 
 
1.53E-02 
 
 
 
2 
 
 
 
51 
 
 
 
2 
 
 
 
0.039 
 
 
 
1 
 
 
 
GO:0060849 
 
 
 
BP 
 
 
 
3 
regulation of transcription 
involved in lymphatic 
endothelial cell fate 
commitment 
 
 
 
1 
 
 
 
NR2F2,PROX1 
 
1 
 
3.15E-02 
 
29 
 
50 
 
3 
 
0.06 
 
0.103 
 
REAC:440430 
 
re 
 
4 
Formation of Fibrin Clot 
(Clotting Cascade) 
 
1 
 
MUG1,A2M,F5 
 
 
 
1 
 
 
 
3.32E-02 
 
 
 
5 
 
 
 
50 
 
 
 
2 
 
 
 
0.04 
 
 
 
0.4 
 
 
 
REAC:434580 
 
 
 
re 
 
 
 
1 
kallikrein + alpha2- 
macroglobulin -> 
kallikrein:alpha2- 
macrogloulin 
 
 
 
1 
 
 
 
MUG1,A2M 
 
1 
 
1.00E-02 
 
3 
 
50 
 
2 
 
0.04 
 
0.667 
 
REAC:431218 
 
re 
 
2 
Exocytosis of alpha 2 
macroglobulin 
 
1 
 
MUG1,A2M 
89 
 
 
 
 
 
 
Down in S+A+F vs S+A 
        
 
# 
 
p-value 
 
T 
 
Q 
 
Q&T 
 
Q&T/Q 
 
Q&T/T 
 
term ID 
 
t type 
 
t group 
t name and depth in 
group 
  
Q&T list 
#             
 
1 
 
2.84E-02 
 
804 
 
49 
 
10 
 
0.204 
 
0.012 
 
GO:0006952 
 
BP 
 
9 
 
defense response 
 
1 
PRKCD,SERPING1,CD4,PLAC8,C4B,OL 
R1,PENK,ADORA2A,CD74,CXCL13 
 
 
 
1 
 
 
 
8.79E-05 
 
 
 
1376 
 
 
 
49 
 
 
 
16 
 
 
 
0.327 
 
 
 
0.012 
 
 
 
GO:0002376 
 
 
 
BP 
 
 
 
2 
 
 
 
immune system process 
 
 
 
1 
MEIS2,CTSC,PRKCD,IGFBP2,SERPING 
1,CD4,RT1- 
A2,ITGAL,IGF2,C4B,FCGR3A,IL2RG,AD 
ORA2A,CD74,CXCL13,RT1-DA 
 
1 
 
1.34E-02 
 
198 
 
49 
 
6 
 
0.122 
 
0.03 
 
GO:0070661 
 
BP 
 
2 
 
leukocyte proliferation 
 
1 
PRKCD,IGFBP2,ITGAL,IGF2,FCGR3A,C 
D74 
 
1 
 
1.06E-02 
 
190 
 
49 
 
6 
 
0.122 
 
0.032 
 
GO:0032943 
 
BP 
 
2 
mononuclear cell 
proliferation 
 
2 
PRKCD,IGFBP2,ITGAL,IGF2,FCGR3A,C 
D74 
 
 
1 
 
 
1.88E-04 
 
 
738 
 
 
49 
 
 
12 
 
 
0.245 
 
 
0.016 
 
 
GO:0006955 
 
 
BP 
 
 
2 
 
 
immune response 
 
 
1 
CTSC,PRKCD,SERPING1,CD4,RT1- 
A2,ITGAL,C4B,FCGR3A,IL2RG,CD74,C 
XCL13,RT1-DA 
 
1 
 
1.73E-02 
 
595 
 
49 
 
9 
 
0.184 
 
0.015 
 
GO:0001775 
 
BP 
 
2 
 
cell activation 
 
1 
PRKCD,IGFBP2,CD4,ITGAL,IGF2,FCGR 
3A,IL2RG,ADORA2A,CD74 
 
1 
 
5.13E-03 
 
512 
 
49 
 
9 
 
0.184 
 
0.018 
 
GO:0045321 
 
BP 
 
2 
 
leukocyte activation 
 
2 
PRKCD,IGFBP2,CD4,ITGAL,IGF2,FCGR 
3A,IL2RG,ADORA2A,CD74 
 
1 
 
1.10E-03 
 
425 
 
49 
 
9 
 
0.184 
 
0.021 
 
GO:0046649 
 
BP 
 
2 
 
lymphocyte activation 
 
3 
PRKCD,IGFBP2,CD4,ITGAL,IGF2,FCGR 
3A,IL2RG,ADORA2A,CD74 
 
1 
 
8.10E-04 
 
296 
 
49 
 
8 
 
0.163 
 
0.027 
 
GO:0042110 
 
BP 
 
2 
 
T cell activation 
 
4 
IGFBP2,CD4,ITGAL,IGF2,FCGR3A,IL2R 
G,ADORA2A,CD74 
 
1 
 
1.03E-02 
 
189 
 
49 
 
6 
 
0.122 
 
0.032 
 
GO:0046651 
 
BP 
 
2 
lymphocyte 
proliferation 
 
4 
PRKCD,IGFBP2,ITGAL,IGF2,FCGR3A,C 
D74 
 
1 
 
1.49E-03 
 
321 
 
49 
 
8 
 
0.163 
 
0.025 
 
GO:0050865 
 
BP 
 
2 
regulation of cell 
activation 
 
2 
PRKCD,IGFBP2,CD4,ITGAL,IGF2,IL2R 
G,ADORA2A,CD74 
 
1 
 
1.13E-02 
 
192 
 
49 
 
6 
 
0.122 
 
0.031 
 
GO:0050867 
 
BP 
 
2 
positive regulation of cell 
activation 
 
2 
 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74 
 
 
1 
 
 
1.34E-03 
 
 
721 
 
 
49 
 
 
11 
 
 
0.224 
 
 
0.015 
 
 
GO:0002682 
 
 
BP 
 
 
2 
 
regulation of immune 
system process 
 
 
1 
MEIS2,IGFBP2,SERPING1,CD4,ITGAL,I 
GF2,C4B,IL2RG,ADORA2A,CD74,CXCL 
13 
 
1 
 
1.16E-02 
 
298 
 
49 
 
7 
 
0.143 
 
0.023 
 
GO:0002694 
 
BP 
 
2 
regulation of leukocyte 
activation 
 
2 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,ADOR 
A2A,CD74 
 
1 
 
4.04E-03 
 
254 
 
49 
 
7 
 
0.143 
 
0.028 
 
GO:0051249 
 
BP 
 
2 
regulation of 
lymphocyte activation 
 
3 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,ADOR 
A2A,CD74 
 
1 
 
4.00E-04 
 
180 
 
49 
 
7 
 
0.143 
 
0.039 
 
GO:0050863 
 
BP 
 
2 
regulation of T cell 
activation 
 
4 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,ADOR 
A2A,CD74 
 
1 
 
1.68E-03 
 
447 
 
49 
 
9 
 
0.184 
 
0.02 
 
GO:0002684 
 
BP 
 
2 
positive regulation of 
immune system process 
 
1 
IGFBP2,SERPING1,CD4,ITGAL,IGF2,C4 
B,IL2RG,CD74,CXCL13 
 
1 
 
8.54E-03 
 
183 
 
49 
 
6 
 
0.122 
 
0.033 
 
GO:0002696 
 
BP 
 
2 
positive regulation of 
leukocyte activation 
 
2 
 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74 
 
1 
 
4.53E-03 
 
164 
 
49 
 
6 
 
0.122 
 
0.037 
 
GO:0051251 
 
BP 
 
2 
positive regulation of 
lymphocyte activation 
 
3 
 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74 
 
1 
 
5.94E-04 
 
116 
 
49 
 
6 
 
0.122 
 
0.052 
 
GO:0050870 
 
BP 
 
2 
positive regulation of T 
cell activation 
 
4 
 
IGFBP2,CD4,ITGAL,IGF2,IL2RG,CD74 
1 4.06E-02 23 49 3 0.061 0.13 GO:0001964 BP 1 startle response 1 DRD2,PENK,ADORA2A 
 
1 
 
1.81E-02 
 
598 
 
49 
 
9 
 
0.184 
 
0.015 
 
GO:0007610 
 
BP 
 
5 
 
behavior 
 
1 
LHX8,TRH,IGF2,DRD2,PENK,ADORA2 
A,CD74,GPR88,CXCL13 
 
 
1 
 
 
2.78E-02 
 
 
1401 
 
 
49 
 
 
13 
 
 
0.265 
 
 
0.009 
 
 
GO:0044459 
 
 
CC 
 
 
12 
 
 
plasma membrane part 
 
 
1 
SCN4B,IGFBP2,CD4,RT1- 
A2,ITGAL,FCGR3A,TRPM6,IL2RG,DRD 
2,RGS9,ADORA2A,CD74,RT1-DA 
 
1 
 
4.99E-02 
 
1 
 
14 
 
1 
 
0.071 
 
1 
 
CORUM:2277 
 
co 
 
7 
D2 receptor-GluR2- 
GluR1 complex 
 
1 
 
DRD2 
 
1 
 
4.99E-02 
 
1 
 
14 
 
1 
 
0.071 
 
1 
 
CORUM:3277 
 
co 
 
10 
D2 receptor-Nsf-GluR2 
complex 
 
1 
 
DRD2 
 
1 
 
6.52E-03 
 
78 
 
49 
 
4 
 
0.082 
 
0.051 
 
KEGG:04612 
 
ke 
 
6 
Antigen processing and 
presentation 
 
1 
 
CD4,RT1-A2,CD74,RT1-DA 
 
1 
 
1.42E-03 
 
53 
 
49 
 
4 
 
0.082 
 
0.075 
 
KEGG:05150 
 
ke 
 
11 
Staphylococcus aureus 
infection 
 
1 
 
ITGAL,C4B,FCGR3A,RT1-DA 
 
1 
 
7.06E-03 
 
152 
 
49 
 
5 
 
0.102 
 
0.033 
 
KEGG:04514 
 
ke 
 
8 
Cell adhesion molecules 
(CAMs) 
 
1 
 
CD4,RT1-A2,CLDN2,ITGAL,RT1-DA 
 
1 
 
1.19E-02 
 
170 
 
49 
 
5 
 
0.102 
 
0.029 
 
KEGG:04145 
 
ke 
 
4 
 
Phagosome 
 
1 
RT1-A2,FCGR3A,CD209B,OLR1,RT1- 
DA 
 
1 
 
4.98E-02 
 
3 
 
49 
 
2 
 
0.041 
 
0.667 
 
REAC:432379 
 
re 
 
3 
Formation of the 
IGF:IGFBP-2 Complex 
 
1 
 
IGFBP2,IGF2 
90  
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